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A B S T R A C T
Background
In many countries intrauterine insemination (IUI) is the treatment of first choice for a subfertile couple when the infertility work up
reveals an ovulatory cycle, at least one open Fallopian tube and sufficient spermatozoa. The final goal of this treatment is to achieve a
pregnancy and deliver a healthy (singleton) live birth. The probability of conceiving with IUI depends on various factors including age
of the couple, type of subfertility, ovarian stimulation and the timing of insemination. IUI should logically be performed around the
moment of ovulation. Since spermatozoa and oocytes have only limited survival time correct timing of the insemination is essential. As
it is not known which technique of timing for IUI results in the best treatment outcome, we compared different techniques for timing
IUI and different time intervals.
Objectives
To evaluate the effectiveness of different synchronisation methods in natural and stimulated cycles for IUI in subfertile couples.
Search methods
We searched for all publications which described randomised controlled trials of the timing of IUI.We searched theCochraneMenstrual
Disorders and Subfertility Group Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL) (1966 to October
2014), EMBASE (1974 to October 2014), MEDLINE (1966 to October 2014) and PsycINFO (inception to October 2014) electronic
databases and prospective trial registers. Furthermore, we checked the reference lists of all obtained studies and performed a handsearch
of conference abstracts.
Selection criteria
Randomised controlled trials (RCTs) comparing different timing methods for IUI were included. The following interventions were
evaluated: detection of luteinising hormone (LH) in urine or blood, single test; human chorionic gonadotropin (hCG) administration;
combination of LH detection and hCG administration; basal body temperature chart; ultrasound detection of ovulation; gonadotropin-
releasing hormone (GnRH) agonist administration; or other timing methods.
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Data collection and analysis
Two review authors independently selected the trials, extracted the data and assessed study risk of bias. We performed statistical analyses
in accordance with the guidelines for statistical analysis developed by The Cochrane Collaboration. The overall quality of the evidence
was assessed using GRADE methods.
Main results
Eighteen RCTs were included in the review, of which 14 were included in the meta-analyses (in total 2279 couples). The evidence was
current to October 2013. The quality of the evidence was low or very low for most comparisons . The main limitations in the evidence
were failure to describe study methods, serious imprecision and attrition bias.
Ten RCTs compared differentmethods of timing for IUI.We found no evidence of a difference in live birth rates between hCG injection
versus LH surge (odds ratio (OR) 1.0, 95% confidence interval (CI) 0.06 to 18, 1 RCT, 24 women, very low quality evidence), urinary
hCG versus recombinant hCG (OR 1.17, 95% CI 0.68 to 2.03, 1 RCT, 284 women, low quality evidence) or hCG versus GnRH
agonist (OR 1.04, 95% CI 0.42 to 2.6, 3 RCTS, 104 women, I2 = 0%, low quality evidence).
Two RCTs compared the optimum time interval from hCG injection to IUI, comparing different time frames that ranged from 24
hours to 48 hours. Only one of these studies reported live birth rates, and found no difference between the groups (OR 0.52, 95%
CI 0.27 to 1.00, 1 RCT, 204 couples). One study compared early versus late hCG administration and one study compared different
dosages of hCG, but neither reported the primary outcome of live birth.
We found no evidence of a difference between any of the groups in rates of pregnancy or adverse events (multiple pregnancy, miscarriage,
ovarian hyperstimulation syndrome (OHSS)). However, most of these data were very low quality.
Authors’ conclusions
There is insufficient evidence to determine whether there is any difference in safety and effectiveness between different methods of
synchronization of ovulation and insemination. More research is needed.
P L A I N L A N G U A G E S U M M A R Y
What is the best timing technique for intrauterine insemination in subfertile couples
Review question. Cochrane authors reviewed the evidence about the effectiveness of different timing techniques for intrauterine
insemination in subfertile couples.
Background.Couples that have not reached pregnancy after trying for at least a year are defined as subfertile. This affects approximately
10% of couples trying to have a baby. A procedure that may assist couples is intrauterine insemination (IUI). This is an assisted
reproduction procedure where sperm are placed directly into the uterus at a specific time in the woman’s menstrual cycle (as close
to ovulation as possible). It remains unclear which technique of timing for IUI results in the best treatment outcome, a healthy live
birth. Timing of IUI is most frequently performed with hormone (luteinising hormone (LH)) detection in urine or blood, or human
chorionic gonadotropin (hCG) injection. The usefulness of urinary LH monitoring is hampered by the possibility of false-negative
results which can cause inaccurate timing and significantly reduce pregnancy rates. On the other hand, the ease of performing a test
at home, the lower costs and the non-invasiveness are advantages. Limitations of timing by ultrasound and hCG administration are
frequent hospital visits and the occurrence of premature LH surges or the possibility of triggering ovulation in the presence of an
immature follicle. The major advantage of this hCG method is the clinical predictability of the ovulation.
Study characteristics. We found 18 randomised controlled trials, all comparing different timing methods in one treatment cycle for
IUI, with a total of 2279 couples. The evidence was current to October 2013.
Key results.We found no evidence of a difference in live birth rates between timing methods. We also found no evidence of a difference
between any of the groups in rates of pregnancy or adverse events (multiple pregnancy, miscarriage, ovarian hyperstimulation syndrome
(OHSS)).
Quality of the evidence. Most of the evidence was of low or very low quality. The main limitations were poor reporting of study
methods, imprecision and losses to follow up. More research is needed.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
hCG compared to LH surge for intrauterine insemination in subfertile couples
Population: women undergoing intrauterine insemination
Intervention: hCG
Comparison: LH surge
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LH surge HCG
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*The basis for the assumed risk was the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison
group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Methods used for random sequence generation and/or allocation concealment were unclear.
2There was very serious imprecision, with small sample sizes and very few events.







































































































B A C K G R O U N D
Description of the condition
Subfertility is usually defined as the inability of a couple to con-
ceive after at least one year of unprotected intercourse. This is
approximately 10% of couples who try to conceive. Subfertility
is considered to be unexplained when an infertility work up con-
sisting of cycle analysis, semen analysis and analysis of at least
one patent Fallopian tube was unable to detect any abnormality.
Couples with male subfertility have repeated semen analyses be-
low the criteria for normal semen as defined by the World Health
Organization (WHO) (WHO 2010). Couples suspected of cervi-
cal hostility used to be diagnosed by a well-timed non-progressive
postcoital test, defined as the absence of spermatozoa moving in a
straight direction and at a functional speed. However, nowadays
the accuracy of this test and the existence of the diagnosis have
been questioned. Finally, mild endometriosis is defined as grade I
or II at diagnostic laparoscopy. When one of these causes for sub-
fertility has been identified and the probability of a spontaneous
pregnancy is low, the first treatment option is often intrauter-
ine insemination (IUI), although couples with a good prognosis
might benefit from expectant management (Steures 2006). The
final goal of this treatment is to achieve a pregnancy and deliver a
healthy (singleton) live birth. The probability of conceiving with
IUI depends on various confounding factors including age of the
couple, type of subfertility, ovarian stimulation and the timing of
insemination (Rahman 2011).
As spermatozoa and oocytes survive for only a limited period of
time, correct timing of IUI seems essential. Therefore, IUI should
logically be performed as close to ovulation as possible.
Description of the intervention
There are several options for timing IUI including luteinising hor-
mone (LH) testing, ultrasound scanning, human chorionic go-
nadotropin (hCG) injection, recombinant LH and gonadotropin-
releasing hormone (GnRH) agonist administration, and basal
body temperature (BBT) charts.
LH levels in urine or blood are one of the most precise predictors
of ovulation. According to the WHO, ovulation in natural cycles
takes place from 24 to 56 hours after the onset of the LH surge,
with a mean time of 32 hours (WHO 1980).
In stimulated cycles, when the dominant follicle(s) reaches a cer-
tain mean diameter hCG is given to induce ovulation; which oc-
curs approximately 36 to 40 hours after hCG injection (Andersen
1995).
GnRH agonist can also be used for final oocyte maturation and
ovulation. GnRH agonists induce an endogenous surge of LH and
follicle-stimulating hormone (FSH), giving a more physiologic
approach than with exogenous hCG. The use of GnRH agonists
is less widespread because of the high costs (Andrés-Oros 2008).
How the intervention might work
Each of these interventions is seeking to predict or synchronise
ovulation, or both, in order to time the IUI to provide the best
pregnancy outcomes.
Why it is important to do this review
Difficulties exist with the different methods of prediction and syn-
chronisation of ovulation. The usefulness of urinary LHmonitor-
ing is hampered by the possibility of false-negative results, which
may occur in up to 23% to 35% of ovulatory cycles. The LH peak
values may be below the limit of detection for the urine ovulation
prediction kit, or the duration of the LH surge is too short to be
easily detected. This can cause inaccurate timing and significantly
lower pregnancy rates. On the other hand, the ease of performing
a test at home, the lower costs and the non-invasiveness are advan-
tages of urinary LH monitoring (Lewis 2006). Timing by ultra-
sound combined with hCG administration is time consuming and
limited by the possible occurrence of premature LH surges and the
possibility of triggering ovulation in the presence of an immature
egg (Cantineau 2007; Cohlen 1998; Martinez 1991a). The major
advantage of this hCG method is the clinical predictability of the
ovulation. A combination of LH surge and hCG administration
may minimise the limitations mentioned above (Kosmas 2006).
This review investigates which approach for synchronisation of
ovulation results in the highest pregnancy and live birth rates for
subfertile couples undergoing IUI.
O B J E C T I V E S
To evaluate the effectiveness of different synchronisation methods
in natural and stimulated cycles for IUI in subfertile couples.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included both published and unpublished randomised con-
trolled trials (RCTs). The method of randomisation was assessed
to determine whether the studies were truly randomised. Cross-
over trials will be included, but only data from the first phase will
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be included in the meta analysis. There were no restrictions based
on trial duration.
Types of participants
Subfertile couples were eligible for inclusion. We included all types
of subfertility where IUI is the first treatment option (for exam-
ple unexplained subfertility, male subfertility, mild endometriosis,
cervical hostility and cycle disturbances).
Routine fertility evaluation should have consisted of confirmed
ovulatory status (by a biphasic basal body temperature chart, mid-
luteal progesterone, or sonographic evidence of ovulation), tubal
patency (by hysterosalpingography or laparoscopy, or both) and
normal results in semen analysis. Subfertilitywas regarded as due to
male factor when at least two separate semen samples did not meet
the WHO criteria of normality. A normal quality semen sample
was described as having a sperm concentration of 20 x 106 permL,
total motility 50%, normal morphology in 50%, and no sperm
antibodies (WHO 1987). In 1992, the WHO changed its criteria
for sperm morphology from 50% to 30% (WHO 1992) and for
recent trials we used the 1992 definition of normality. Trials before
1992 should have used the WHO criteria of 1987. When strict
criteria for morphology were used > 14% was considered normal
(Kruger 1993). Since 2010 the reference values have been adapted
and the most important changes are: semen volume of 1.5 mL,
a sperm concentration of 15 x 106 per mL, total motility 40%
and normal morphology in 4% (Cooper 2010; WHO 2010). For
future trials these criteria will be applied.
Mild endometriosis was defined as grade I or II at diagnostic la-
paroscopy. Cervical factor was defined as a negative result with
well-timed postcoital testing. We reported in the review the dif-
ferences between trials in defining the types of subfertility. Slight
differences did not lead to exclusion.
Types of interventions
RCTs comparing any two of the following interventions in couples
undergoing IUI were eligible for inclusion:
• LH detection in urine or blood, single test;
• hCG administration;
• a combination of LH detection and hCG administration;
• the use of basal body temperature charts;
• ultrasound detection of ovulation;
• GnRH agonist administration;
• other timing methods.
We included both natural cycles and stimulated cycles and consid-
ered them separately.We included all types of ovarian stimulation.
We excluded trials comparing synchronisation methods using in-
semination techniques other than IUI, such as timed intercourse,
intracervical insemination, gamete intrafallopian transfer (GIFT)
and fallopian tube sperm perfusion.
Types of outcome measures
Primary outcomes
• Live birth rate per couple
Secondary outcomes
• Clinical pregnancy rate per couple (pregnancy rate per
couple)
• Ongoing pregnancy rate per couple
• Optimal time interval from the hCG injection to IUI
• Costs of each method of timing (per treatment cycle)
Adverse outcomes
• Multiple pregnancies (multiple pregnancy rate per couple
and per pregnancy)
• Miscarriage rate (miscarriage rate per couple and per
pregnancy)
• Ovarian hyperstimulation syndrome (OHSS) per couple
• Tubal pregnancy (tubal pregnancy rate per couple)
• Dropouts (dropout rate per couple)
Clinical pregnancy was established by a positive hCG test in blood
or urine and confirmed by ultrasound at around seven weeks of
gestation. Ongoing pregnancy was defined as a pregnancy that
extended beyond 12 weeks of gestation, confirmed by ultrasound.
Multiple pregnancies were confirmed by ultrasound or delivery.
We included pregnancies in which selective reduction was per-
formed, mentioning the original number of fetuses.
We defined a dropout as a couple leaving the study protocol after
randomisation.
Not all outcomemeasures needed to be available to include a study.
Search methods for identification of studies
Electronic searches
We searched for all publications which described (or might de-
scribe) RCTs of synchronisation of ovulation with IUI in natural
and stimulated cycles. No language restrictions weremade and the
search was performed in consultation with the Menstrual Disor-
ders and Subfertility Group (MDSG) Trials Search Co-ordinator.
• The Cochrane Menstrual Disorders and Subfertility Group
Specialised Register of controlled trials (from inception to
October 2014) (Appendix 1).
• The Cochrane Central Register of Controlled Trials
(CENTRAL; October 2014) (Appendix 2).
• The electronic databases of MEDLINE (inception to
October 2014) (Appendix 3).
• EMBASE (inception to October 2014) (Appendix 4).
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• PsycINFO (inception to October 2014) (Appendix 5).
The MEDLINE search was combined with the Cochrane highly
sensitive search strategy for identifying RCTs, which appears in
theCochrane Handbook for Systematic Reviews of Interventions (Ver-
sion 5.1.0; Chapter 6, 6.4.11) (Higgins 2011). The EMBASE
search was combined with the trial filter developed by the Scot-
tish Intercollegiate Guidelines Network (SIGN) (www.sign.ac.uk/
mehodology/filters.html#random).
Other electronic sources of trials included the following.
• Trial registers for ongoing and registered trials:
’ClinicalTrials.gov’ a service of the US National Institutes of
Health (http://clinicaltrials.gov/ct2/home), and the WHO
International Clinical Trials Registry Platform search portal
(http://www.who.int/trialsearch/Default.aspx).
• Conference abstracts in the Web of Knowledge (http://
wokinfo.com/).
• LILACS database, as a source of trials from the Portuguese
and Spanish speaking world (htpp://regional.bvsalud.org/php/
index.php?lang=en) (choose ’LILACS’ in ’all sources’ drop-down
box).
• PubMed (http://www.ncbi.nlm.nih.gov/pubmed/).
• OpenSIGLE database for grey literature from Europe (http:
//opensigle.inist.fr/).
We searched the databases using the medical subject headings
(MsSH terms) and keywords in Appendix 6.
Searching other resources
• We checked the reference lists of all identified studies for
relevant articles.
• We performed a handsearch of abstracts of the American
Society for Reproductive Medicine (1999 to October 2014) and
the European Society for Human Reproduction and Embryology
(1997 to October 2014) meetings.
When important information was lacking from the original pub-
lications we tried to contact the authors. We incorporated addi-
tional information in the review.
Data collection and analysis
Selection of studies
After screening the titles and abstracts retrieved by the search, full
texts of all potentially eligible studies were obtained. MJ Janssen
and AEP Cantineau independently selected the trials to be in-
cluded according to the above mentioned criteria. We resolved
disagreements by consensus or through arbitration by BJ Cohlen.
We performed an analysis of agreement for inclusion between the
two review authors using the crude percentage agreement. This
analysis was performed on the primary comparison, the method
of randomisation and concealment of allocation. If it was not clear
whether a criterion was met, we tried to contact the authors.
Data extraction and management
The same two review authors independently used a data extraction
form to extract the data from published reports. We resolved dis-
agreement as described above. This data extraction form includes
information on the type of study, quality of the selected studies,
types of participants, types of interventions and the types of out-
come measures. An analysis of agreement between the two review
authors on assessment of the method of randomisation and study
design resulted in 100% agreement.
Type of studies
Randomised controlled trials (RCTs) only.
Trial quality
1. Randomisation:
• truly randomised, e.g. blocked randomisation list, on-site
computer system, centralised randomisation scheme, random
number tables or drawing lots;
• stated without further description, or not stated.
Studies which claimed to be randomised but the method of ran-
domisationwas not described or not described indetail were placed
in the category ’stated without further description’. We included
these studies in the ’waiting for assessment’ group and contacted
the authors for additional information.
2. Concealment of allocation:
• adequate (low risk of bias), e.g. sealed opaque envelopes or
third party randomisation;
• inadequate (high risk of bias), e.g. open list of random
numbers, open envelopes, tables;
• stated without further description or not stated (unclear
risk of bias).
Studies with an allocation low risk of bias or unclear risk of bias
were included in the meta-analysis.
3. Study design:
• parallel design, cross-over design or not clear (we included
only parallel group studies or data before cross over, we
designated studies that were unclear as ’awaiting assessment’);
• single centre or multi-centre;
• inclusion criteria, exclusion criteria;
• groups similar at baseline regarding the most important
prognostic indicators, yes (included), no (excluded), not stated.
4. Blinding:
• were the couple, the care provider and the outcome assessor
blinded?
5. Analysis:
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• by intention to treat (ITT);
• power calculation (prospective power calculation, no power
calculation or not stated).
6. Dropouts:
• percentage of dropouts;
• reasons for and details on dropouts (selective dropout?).
7. Cancelled cycles:
• percentage of cancelled cycles < 10% (> 10% cancelled
cycles then mentioned but excluded from meta-analysis);
• reasons for cancelled cycles.
8. Follow up:
• duration of follow up;




• type of subfertility;
• primary or secondary subfertility;
• duration of subfertility;
• semen quality;
• body mass index.
10. Basic fertility work up:
• regular menstrual cycles with biphasic body temperature
charts or normal luteal progesterone;
• patent tubes on hysterosalpingography or laparoscopy, or
both.
11. Previous fertility treatment:
• tubal surgery;




• type and dosage of drugs for mild ovarian hyperstimulation;
• days of ovarian stimulation;
• number of dominant follicles (> 10 mm);
• cancellation criteria, risk of multiple pregnancies or OHSS;
• use of luteal support;
• allowance of unprotected intercourse during treatment.
13. Semen sample preparation techniques:
• type of semen injected, e.g. cryopreserved donor, partner’s
fresh semen;
• amount of semen injected, number of motile spermatozoa;
• method of sperm preparation (washing and centrifugation
technique, swim up technique, other).
14. Insemination characteristics:
• type of insemination catheter;
• use of single or double insemination;
• number of treatment cycles;
• actual timing of IUI (time from LH detection to IUI, time
from hCG administration to IUI).
Type of outcome measures
15. Primary outcomes:
• the number of live births.
16. Secondary outcomes:
• the number of clinical (total and ongoing) pregnancies.
17. Adverse outcomes:
• incidence of miscarriage, multiple pregnancies, OHSS,
tubal pregnancy.
18. Best time interval for insemination.
19. Costs of each method.
Assessment of risk of bias in included studies
Data for trial characteristics which have been recognised as po-
tential sources of bias, such as the method used in generating the
allocation sequence, how allocation was concealed, comparabil-
ity of participants’ baseline variables, and differences in dropout
rates between study arms, were independently determined by MJ
Janssen and AEP Cantineau as part of the data collection pro-
cess. The criteria outlined in theCochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0 (Higgins 2011) were used.
Where there was uncertainty, authors were contacted to clarify
aspects of study design. Differences in agreement between review
authors were resolved as described above.
Two review authors independently assessed the included studies
for risk of bias using the Cochrane risk of bias assessment tool
(www.cochrane-handbook.org) using the following domains:
• selection bias (random sequence generation and allocation
concealment);
• performance bias (blinding of participants and personnel);
• detection bias (blinding of outcome assessment);
• attrition bias (incomplete outcome data);
• reporting bias (selective reporting);
• other bias.
These domains were assessed to have:
• high risk of bias;
• unclear risk of bias;
• low risk of bias.
Disagreements were resolved by discussion or by a third review
author. We described all judgements fully and presented the con-
clusions in the risk of bias table, which was incorporated into the
interpretation of review findings by means of sensitivity analyses.
We judged that blinding of the researcher, the personnel or the
participants could not influence the outcomes live birth rate, clin-
ical pregnancy rate, miscarriage rate or any of the other outcomes.
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All included trials were therefore assessed as low risk of bias for
blinding.
According to the Cochrane Handbook for Systematic Reviews of In-
terventions, a trial with missing data was judged as low risk of bias
if the missing data were addressed adequately, there was no imbal-
ance between intervention groups and the missing data were not
related to the outcome.
Measures of treatment effect
We performed statistical analyses in accordance with the guide-
lines for statistical analysis developed by The Cochrane Collabo-
ration, outlined in the Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 (Higgins 2011).
For dichotomous data, we expressed results for each included study
as Mantel-Haenszel odds ratios (OR) with 95% confidence inter-
vals (CI).
Unit of analysis issues
The primary analysis was per woman randomised. If an included
study only reported per cycle data, the author was contacted for
additional information. Studies that could not provide us with
per woman data were included in the review but not in the meta-
analysis, and were described separately. We included both parallel
group and cross-over trials in the analysis. For cross-over trials we
used only the first cycle(s) before ’crossing over’ when the data
required were available.
Furthermore, multiple live births were counted as one live birth
event.
Dealing with missing data
For missing data, we attempted to contact the investigators. When
we could not obtain the missing data from the investigators, we
explained the assumptions we made in the extraction and analysis
of the data.
Assessment of heterogeneity
We noted statistical heterogeneity between the results of different
studies by visually inspecting the scatter in the data points on the
graphs and the overlap in their CIs and using the I² statistic. Ac-
cording to the Cochrane Handbook for Systematic Reviews of Inter-
ventions, an I² value greater than 50% was judged to indicate sub-
stantial heterogeneity. In the case of statistical heterogeneity, we
planned to use a random-effects model instead of the fixed-effect
model, and to explore the original trials for clinical and method-
ological heterogeneity.
Assessment of reporting biases
Besides statistical and clinical heterogeneity, publication bias
might influence the interpretation of the pooled results. To detect
publication bias we planned to construct a funnel plot, plotting
sample size versus effect size, if there were sufficient studies. This
plot is only relevant when five or more studies per comparison are
included. The graph is symmetrical when bias is absent.
Data synthesis
If appropriate, we combined the data in a meta-analysis with
RevMan software (RevMan 5), using a fixed-effect model.
We considered live birth rate and pregnancy outcomes as a positive
consequence of treatment. Therefore, a higher proportion achiev-
ing these outcomes was considered a benefit. For adverse outcomes
such as multiple pregnancy rate, miscarriage rate and OHSS rate,
which are negative consequences, higher numbers were consid-
ered to be detrimental (increased odds signify relative harm). This
needs to be taken into consideration when interpreting the meta-
analyses.
Subgroup analysis and investigation of heterogeneity
Apriori, we planned to perform separate subgroup analyses if there
were more than two studies in each subgroup, for trials which
differed in the following.
• Subfertility causes: male factor, unexplained, cervical
hostility, mild endometriosis.
• Ovarian stimulation protocols: oral ovulation induction
agents (anti-estrogens) versus gonadotropins (follicle-stimulating
hormone (FSH), human menopausal gonadotropin (HMG)).
• LH monitoring: once or twice daily, serum LH versus
urinary LH.
Sensitivity analysis
We conducted the following sensitivity analyses for the primary
outcome, to examine stability regarding the pooled outcomes.
• Restriction to studies without high risk of bias.
• Use of a random-effects model.
• Use of relative risk rather than odds ratio.
Overall quality of the body of evidence: summary of
findings table
Weprepared a summary of findings table usingGRADEPRO soft-
ware. This table evaluated the overall quality of the body of evi-
dence for the review outcomes using GRADE criteria (study limi-
tations that is risk of bias, consistency of effect, imprecision, indi-
rectness and publication bias). Judgements about evidence quality
(high, moderate or low) were justified, documented and incorpo-
rated into reporting of results for each outcome.
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R E S U L T S
Description of studies
Results of the search
When this review was first published, we identified 95 articles
relating to the subject. Of these, 39 were excluded as their title and
abstract very clearly did not meet the basic inclusion criteria. The
remaining 56 articles were analysed in detail, of which 10 studies
were included, 2 studies were awaiting assessment and 1 study was
defined as ongoing.
When updating the review in 2014 we performed the search again
and 113 additional articles were found with the adapted search
strategy; 21 studies were identified which potentially provided
data comparing different timing modalities. Of these, 11 were ex-
cluded when analysed in detail by two review authors (AC and
MJ) (Casadei 2006; Gerrits 2011; Ghanem 2011; Ghazizadeh
2009; Ghosh Dastidar 2009; Panchal 2009; Propst 2012; Ramon
2009; Ramon 2009a; Tonguc 2010). Further evaluation based on
the inclusion criteria showed six new trials were eligible for inclu-
sion in the review (AboulGheit 2010; da Silva 2012; Kyrou 2012;
Nikbakht 2012; Rahman 2011; Sharma 2011). Furthermore, one
study was included from the awaiting assessment category of 2009
(Schmidt-Sarosi 1995) and one studywas included from the ongo-
ing trial section (Weiss 2010). The remaining study in the await-
ing assessment category (Propst 2007) was excluded. Four stud-
ies have been added to the awaiting assessment category (Aydin
2013; Blockeel 2014; Dehghani 2014; Mostafa 2014). One study
is ongoing (OVO R&D 2012). Thus, eight studies were included
in addition to the results of the first published version. Full agree-
ment was obtained regarding all trials (see Figure 1).
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Figure 1. Study flow diagram for 2009 to 2013 literature searches.
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The study characteristics and inclusion and exclusion criteria for
each study are described in the tables Characteristics of included
studies and Characteristics of excluded studies.
Included studies
Eighteen studieswere included in total (AboulGheit 2010; Andrés-
Oros 2008; Claman 2004; da Silva 2012; Kyrou 2012; Lewis
2006; Lorusso 2008; Martinez 1991a; Martinez 1991b; Nikbakht
2012; Rahman 2011; Sakhel 2007; Scott 1994; Shalev 1995;
Sharma 2011; Schmidt-Sarosi 1995;Weiss 2010; Zreik 1999) (see
Characteristics of included studies). Twelve compared different
synchronisation approaches, four compared the optimum time in-
terval from the onset of hCG injection to IUI (AboulGheit 2010;
Claman 2004; Rahman 2011; Weiss 2010), one study compared
different dosages of hCG injection (Nikbakht 2012) and one study
compared early hCG injection (dominant follicle of 16.0 to 16.9
mm)with late hCG injection (dominant follicle 18.0 to 18.9 mm)
(da Silva 2012). The study of Lewis 2006, both studies ofMartinez
1991a, and the study of Zreik 1999 were used in ameta-analysis to
compare the methods of urinary LH surge versus hCG injection
(264 women, 242 first cycle treatments). The study of Kyrou 2012
compared the methods of serum LH detection versus hCG injec-
tion in natural cycles. All other studies used some form of ovarian
stimulation. Two studies (Lorusso 2008; Sakhel 2007) compared
the use of recombinant hCG versus urinary hCG (409 women,
441 cycles) and five studies (Andrés-Oros 2008; Schmidt-Sarosi
1995; Scott 1994; Shalev 1995; Sharma 2011) compared the use
of hCG versus a GnRH agonist for timing IUI (4 studies, 206
women, 486 cycles). The abstract of Sharma 2011 reported 450
included women but the number of cycles was unclear and the
pregnancy rates were expressed in percentages only. Therefore the
study was not included in the meta-analysis. The study of Claman
2004 was not used in a meta-analysis because only per cycle data
were available (75 women, 189 cycles). The study of Kyrou 2012
was not used in the meta-analysis since more than half of the
women underwent insemination for other reasons than subfertil-
ity, and there were no data available for the group with subfertil-
ity alone (Kyrou 2012). Finally, the study of Weiss 2010 was not
included in the meta-analysis since data per cycle were available
with couples who dropped out after randomisation excluded from
the analysis (see Characteristics of included studies).
Participants
The age of the participants was stated in all but one trial (Sharma
2011) as either a mean with the standard deviation (SD) for each
treatment group or overall. The mean age ranged from 26 to 34
years. There were no statistical differences recorded between the
various treatment groups based on age.
All studies included different types of subfertility: unexplained
subfertility, mild endometriosis, male factor, cervical factor and
tubal or pelvic factor. The study population of Kyrou 2012 con-
tained 58% of women without subfertility (lesbian, single mother)
as stated above. Seven studies (Claman 2004; Nikbakht 2012;
Sakhel 2007; Schmidt-Sarosi 1995; Shalev 1995; Weiss 2010;
Zreik 1999) also included women with ovulatory disorders. In the
studies of Claman 2004 andZreik 1999 the womenwith ovulatory
disorders comprised less than 15% of all women. In the studies
of Sakhel 2007 and Schmidt-Sarosi 1995 these women comprised
around 25% of the total group. In the study of Shalev 1995 69%
of the total group of participants had cycle disorders. In all five
studies they were equally distributed between the two treatment
arms. In the studies of Nikbakht 2012 andWeiss 2010 the number
and distribution of these women were not described. Finally, the
study of da Silva 2012 included a category ’female factor’ (23.4%)
without describing details of this group.
The duration of subfertility was given in 10 trials (AboulGheit
2010; da Silva 2012; Lorusso 2008; Martinez 1991a; Martinez
1991b; Nikbakht 2012; Rahman 2011; Sakhel 2007;Weiss 2010;
Zreik 1999). In two studies (AboulGheit 2010; Sakhel 2007) the
duration was significantly different between the treatment groups.
AboulGheit 2010 reported a mean duration of subfertility of 5.6
years in the 24 hours after hCG group compared to a mean of 3.1
and 3.5 years in the 34 hours and 48 hours after hCG groups. Al-
though the pregnancy rates in the first group were lower compared
to the other groups, this was not significant. Sakhel 2007 reported
a longer duration of subfertility in the group treated with urinary
hCG. This difference still remained a factor after analysing the
data using logistic regression analysis with clinical pregnancy rate
as the dependent variable and controlling for duration of infertil-
ity. They did not state if the difference was of any clinical relevance.
In the studies of Martinez and co-workers the mean duration of
subfertility was 5.6 and 6.3 years, which was quite long and could
have negatively influenced their outcome parameters.
Four studies (da Silva 2012; Nikbakht 2012; Sakhel 2007; Weiss
2010) mentioned the number of couples with primary versus sec-
ondary subfertility. Their populations contained between 36%
and 68.5% with primary subfertility.
Eight studies (da Silva 2012; Kyrou 2012; Lewis 2006; Martinez
1991a; Schmidt-Sarosi 1995; Shalev 1995; Sharma 2011; Zreik
1999) stated that they had included women who had undergone
previous fertility treatment. Most of the women in the studies of
Lewis 2006, Schmidt-Sarosi 1995 andZreik 1999 hadbeen treated
with clomiphene citrate without IUI. Three studies (da Silva 2012;
Martinez 1991a; Sharma 2011) included women who previously
had undergone IUI treatment cycles. Kyrou 2012 and Shalev 1995
did not mention the type of previous fertility treatment.
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Interventions
Three (Lewis 2006;Martinez 1991b; Zreik 1999) of the four stud-
ies comparing urinary LH versus hCG injection used clomiphene
citrate as a method of ovarian stimulation. Clomiphene citrate
was used either from cycle days three to seven or cycle days five
to nine. The fourth study used HMG (Martinez 1991a). One
study compared serum LH versus hCG injection in a natural cycle
(Kyrou 2012). The studies Lorusso 2008 and Sakhel 2007 com-
paring recombinant hCG (r-hCG) with urinary hCG (u-hCG)
both used recombinant FSH (r-FSH) for ovarian stimulation.
However, Sakhel 2007 also added hMG and when the E2 level
exceeded 300 pg/mL, or a leading follicle of more than 14 mm
diameter was present, a gonadotropin-releasing hormone antag-
onist was applied. The studies comparing hCG with a GnRH
agonist (Andrés-Oros 2008; Schmidt-Sarosi 1995; Scott 1994;
Shalev1995; Sharma2011) used different ovarian stimulationpro-
tocols including clomiphene citrate (Schmidt-Sarosi 1995; Scott
1994; Sharma 2011), FSH (Andrés-Oros 2008) and hMG (Shalev
1995). Different stimulation protocols were also used in the stud-
ies trying to define the optimal timing of IUI. Rahman 2011 used
clomiphene citrate as a method of ovarian stimulation, Claman
2004 and Weiss 2010 used hMG or r-FSH. Only AboulGheit
2010 compared the optimal timing of IUI after hCG in natural
cycles. The study of da Silva 2012 compared early hCG with late
hCG depending on the size of the dominant follicle, stimulated
with highly purified HMG. Finally, the study of Nikbakht 2012
comparing two doses of r-hCG achieved ovarian hyperstimulation
with clomiphene citrate or letrozole and HMG
Urinary LH versus hCG injection
The use of the technique for timing IUI was one of the compar-
isons of interest in this review. Lewis 2006 included one group
of women which used a home ovulation predictor kit once a day:
in the afternoon, starting on day 12. Insemination was scheduled
the morning after the first positive test. The women in the hCG
group started ultrasound monitoring on day 12 and 10,000 IU
hCG was given when there was at least one follicle with a mean
diameter of 20 mm and the endometrial thickness was at least 8
mm. A single IUI was scheduled 33 to 42 hours later. Any woman
who did not satisfy criteria for hCG administration was instructed
to perform home monitoring for an LH surge until their next ul-
trasound, and to schedule an insemination if her predictor kit gave
a positive result. There were no details on how often LH surges
were detected in the ultrasound group before a follicle reached the
size of 20 mm.
Martinez 1991a started daily ultrasound scanning when total uri-
nary estradiol excretion exceeded 200 mmol/24 hours. When the
largest follicle reached a diameter between 18 and 20mmon ultra-
sound and the total estradiol excretion was between 300 and 1200
nmol/24 hours women received 10,000 IU hCG. LH detection
in the urine was done twice daily from the moment the dominant
follicle reached the size of 15 mm. A single IUI was performed
36 to 40 hours after hCG administration or 16 to 28 hours after
urinary LH surge detection.
Martinez 1991b started urinary LH monitoring twice a day when
the dominant follicle had reached 15 mm in diameter. Women
were inseminated 21 hours after an evening positive urine or 24
hours after a morning positive urine. The other treatment group
received 10,000 IU hCGwhen the dominant follicle reached a di-
ameter size between 18 and 22 mm,measured daily by ultrasound
when a dominant follicle had reached the size of 15 mm. From 37
to 40 hours after hCG a single IUI was performed.
Zreik 1999 started urinary LHmonitoring in the morning on day
10 of the cycle. Ultrasound monitoring in the hCG group started
on day 10 and 10,000 IU hCG was given when a leading follicle
with diameter 18 mm diameter was noted. In both groups IUI
was performed daily for the next two days.
Serum LH versus hCG injection
Kyrou 2012 was the only study using serum LH testing instead
of urinary LH testing. The daily monitoring of serum LH levels
could start from day 6 of the cycle until the LH rise. When LH
started to rise, a second assessment was performed the next day
to confirm the LH rise. Criteria for detection were an LH rise of
180% above the latest serum value. In the hCG group women
received 5000 IU of hCG as soon as a follicle reached a diameter
of ≥ 17 mm. A single IUI was performed 36 h after initiation of
the LH rise or 36 h after the hCG injection. In the case where the
serum LH suggested an imminent ovulation (LH rise and rise in
progesterone) the insemination was performed after 24 h.
Recombinant hCG (r-hCG) versus urinary hCG (u-hCG)
Lorusso 2008 monitored ovarian response by ultrasound only.
Urinary or recombinant hCG was given when one follicle with a
mean diameter of 18 mm or more was present or no more than
three follicles had a mean diameter of 16 mm. Double IUI was
carried out 24 and 48 hours after administration, except when
ovulation had occurred after 24 hours.
Sakhel 2007 monitored ovarian response by ultrasound and serum
PGE2. When two or more follicles were 16 mm, with 200 pg/mL
E2 per follicle, 10,000 IU u-hCG or 250 mg r-hCG was used to
induce ovulation. A single IUI was performed 42 hours after the
injection but this could be delayed by four hours when there was
no collapse of the leading follicle observed on ultrasound. Luteal
support was added with progesterone.
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hCG versus GnRH agonist (GnRH-a)
Andrés-Oros 2008 administered a single injection of triptorelin
(0.2 mg) or a single injection of r-hCG (250 µg) when at least one
follicle, and not more than three, reached the size 18 mm or more.
A single IUI was performed 36 hours after the injection. Luteal
support with progesterone was applied.
Schmidt-Sarosi 1995 began ultrasound monitoring from cycle day
11. When the largest follicle was > 20 mm, 400 µg nafarelin in-
tranasally (IN) was given on this and the following day, IUI was
performed 48h after the first dose. The hCG group received an in-
tramuscular injection of 5000 IU when the largest follicle reached
> 20 mm and IUI was performed after 36 h. Luteal support in the
GnRH-a group was given as seven doses of 400 µg nafarelin every
16 hours started 6 days after the first dose. Women in the hCG
group received one injection of 2500 IU hCG six days after the
primary injection.
Scott 1994 started daily pelvic ultrasound on cycle day 12. When
the dominant follicle reached a diameter of 20 to 21 mm the
women received GnRH-a (2 mg leuprolide acetate) subcuta-
neously or 10,000 IU hCG intramuscularly. Approximately 40
hours after injection, these women underwent a single IUI after a
pelvic ultrasound was performed.
Shalev 1995 administered a single injection of triptorelin (0.1 mg)
or single injection hCG (10,000 IU) when at least one follicle
attained a diameter of 16 mm. Double IUI was performed 24 and
48 hours after the injection.
Sharma 2011 started follicle monitoring from cycle day 10. Uri-
nary hCG (5000 IU) or GnRH-a (leuprolide 1 mg) was given
when a follicular diameter was between 18 and 20 mm with en-
dometrial thickness ≥ 7 mm. A single IUI was performed only
after confirmation of ovulation with ultrasound. Luteal support
was given with 300 mg vaginal micronized progesterone daily for
15 days.
Optimal time interval
Four studies compared the optimum time interval from ovula-
tion induction to IUI. AboulGheit 2010 triggered ovulation with
highly purified hCG (Choriomon, 10,000 IU) intramuscular in-
jection when the leading follicle reached ≥ 18 mm and when at
least two follicles reached≥ 16 mm. Timing of IUI was 24 hours,
34 hours and 48 hours after hCG.
In the study of Claman 2004 the women received 5000 IU hCG
intramuscularly or 10,000 IU hCG subcutaneously when two to
five follicles were seen on ultrasound with a mean diameter of 17
to 21 mm. Timing of IUI was between 32 and 34 hours or 38 and
40 hours after hCG.
Rahman 2011 started ultrasound monitoring from cycle day 11 or
earlier depending on the women’s cycles. An ovulation trigger was
given with injection of 5000 IU hCG when at least one follicle
reached 18 mm or more and endometrial thickness was at least
7 mm. Single insemination was performed 24 or 36 hours after
hCG injection.
Weiss 2010 administered hCG after a cycle with mild ovarian
stimulation using gonadotropins andGnRH antagonist. The time
and amount of hCG administered was not mentioned, but if five
or more follicles over 15 mm were developed, or if ovulation took
place before administration of the GnRH antagonist, the couple
was excluded. Insemination tookplace 36h, 42h or 48h after hCG
administration. Luteal support was given with endometrin 100
mg twice a day from insemination until eight weeks of gestation.
Size of follicle at hCG injection
da Silva 2012 administered HMG from cycle day 4. Dose adjust-
ments were made according to ovarian response until the criteria
for hCG administration were met; 5000 IU of hCG was injected
when the dominant follicle was between 16.0 and 16.9 mm diam-
eter and 18.0 and 18.9 mm, respectively, and approximately 36
hours later IUI was performed. Luteal support was obtained with
natural micronized progesterone 600 mg/day vaginally.
Two doses of recombinant hCG
In Nikbakht 2012 clomiphene or letrozole and HMG (Pergonal)
were administered. When two or more follicles were 16 mm, r-
hCG 250 or 500 ug was used to induce ovulation. A single IUI
was performed 42 hours after r-hCG injection.
The studies used partners’ semen, although this was not noted
explicitly in all studies. Three studies noted donor cycles (Kyrou
2012; Lewis 2006; Weiss 2010). Semen preparation techniques,
the amount of semen fluid injected, the number of motile semen
injected and the type of insemination catheter were poorly de-
scribed or not described at all (see table Characteristics of included
studies).
Outcomes
Seven trials (Martinez 1991a; Rahman 2011; Sakhel 2007;
Schmidt-Sarosi 1995; Scott 1994; Shalev 1995; Weiss 2010) re-
ported live birth rates. All but one trial (Claman 2004) assessed
pregnancy rate per couple. In one study (Weiss 2010) the couples
who dropped out after inclusion were not included in the calcu-
lation of the live birth rate and pregnancy rate per couple. There-
fore, the latter study was excluded from the meta-analysis.
Multiple pregnancy rates and miscarriage rates were reported
in 11 studies (Andrés-Oros 2008; da Silva 2012; Lewis 2006;
Lorusso 2008; Martinez 1991a; Martinez 1991b; Sakhel 2007;
Schmidt-Sarosi 1995; Scott 1994; Shalev 1995; Weiss 2010).
AboulGheit 2010 reported chemical pregnancies and clinical preg-
nancies separately. The OHSS rate was stated in five studies
(Lorusso 2008; Martinez 1991a; Sakhel 2007; Schmidt-Sarosi
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1995; Shalev 1995) and the ectopic pregnancy rate was stated in
two publications (Sakhel 2007; Weiss 2010).
One of the studies assessed the costs of the treatment (Lewis 2006).
The cost per pregnancy in the LH group was estimated to be USD
3695 and the cost per pregnancy in the hCG group was USD
4830.
Four studies (AboulGheit 2010; Lewis 2006; Nikbakht 2012;
Sakhel 2007) diagnosed pregnancy by a rising concentration of
hCG. In two studies (Lewis 2006; Rahman 2011) the pregnancy
was called viable when a fetal pole with cardiac activity was noted
on ultrasound. Five studies (AboulGheit 2010; da Silva 2012;
Martinez 1991a; Martinez 1991b; Nikbakht 2012) stated that an
ultrasound detection of fetal heart rate activity was performed four
weeks after conception and in the study of Kyrou and co-workers
ultrasound detection of fetal heart rate activity was performed 10
weeks after conception. Five studies (Andrés-Oros 2008; Lorusso
2008; Shalev 1995; Sharma 2011; Weiss 2010) defined clinical
pregnancy by the presence of a gestational sac in the uterus, deter-
mined by transvaginal ultrasound. Three studies (Schmidt-Sarosi
1995; Scott 1994; Zreik 1999) did not mention the method of
confirming pregnancy.
Studies awaiting assessment
All studies previously awaiting assessment were included (noting
that the risk of bias was high, see table Characteristics of included
studies).
Attempts have been made to contact authors to get further infor-
mation about the methods of randomisation, to retrieve unpub-
lished data and for details about published data. Eight replies have
been received, resulting in exclusion of four trials (Diaz 2003a;
Diaz 2003b; Lewis 2003; Pierson 2002) and inclusion of three
trials (Scott 1994; Shalev 1995; Weiss 2010).
Four new studies (Aydin 2013; Blockeel 2014; Dehghani 2014;
Mostafa 2014) that were identified will be assessed when this re-
view is next updated.
Ongoing trials
One trial with the comparison of interest is registered on the Clin-
icalTrials.gov database and is still recruiting couples (OVO R&D
2012) (see Characteristics of ongoing studies). One of the ongoing
trials of the 2009 review has been included (Weiss 2010).
Excluded studies
Fifty-five studies were excluded (see table Characteristics of
excluded studies). Reasons for exclusion were: failure to use a truly
randomised design (n = 19) (Agarwal 1995; Cedrin-Durnerin
1993; Check 1994; Costa Franco 2006; Diaz 2003a; Diaz 2008;
Fondop 2005; Gerris 1995; Ghanem 2011; Khattab 2005; Kossoy
1989; Martinez 1994; Meherji 2004; Panchal 2009; Romeu
1997a; Romeu 1997b; Shanis 1995; Tavaniotou 2003; Tonguc
2010), not performing the comparison of interest (n = 18) (Arici
1994; Baroni 2001; Casadei 2006; Federman 1990; Fischer 1993;
Gerrits 2011; Ghazizadeh 2009; Ghosh Dastidar 2009; Kotecki
2005; Nulsen 1993; Papageorgiou 1995; Pierson 2002; Pirard
2005; Ragni 1999; Ramon 2009; Robinson 1992; Silverberg
1991; Wang 2006), not performing IUI (n = 5) (Barratt 1989;
Claraz 1989; George 2007; Odem 1991; Scarpellini 1991), did
not meet the inclusion criteria for types of participants (n = 2)
(Egbase 2003; Int rhCG study group 2001), or duplicate pub-
lications of abstracts or full text articles (n = 8) (Claman 2000;
Claman 2004a; Diaz 2003b; Lewis 2002; Lewis 2003; Ramon
2009a; Sakhel 2004;Wang 2001). Finally, one study was excluded
from the awaiting assessment category since we did not receive the
information we needed about the randomisation method (n = 1)
(Propst 2007). The same authors published an abstract in 2012 on
the same subject. The research population described seems to be
the same group as published before. Additional information was
lacking, thus this abstract was excluded as well (Propst 2012).
Risk of bias in included studies
Figure 2 presents our judgements about eachmethodological qual-
ity item, presented as percentages across all included studies, and
Figure 3 summarises our judgements about each methodological
quality item for each included study.
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Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 3. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
16Synchronised approach for intrauterine insemination in subfertile couples (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Study design
Four studies (Martinez 1991a;Martinez 1991b; Scott 1994; Zreik
1999) used a cross-over design, with pre-cross over data available.
For the meta-analysis we only included the first cycle data from
these cross-over studies. The trial design was parallel group in the
other included studies.
Allocation
The description of methods for randomisation or allocation con-
cealment was generally poor in the published information, which
might increase the risk for selection bias. However, additional in-
formation was received about allocation methods for most studies.
Random sequence generation
Nine studies mentioned the use of a computer generated pro-
gram for randomisation (Andrés-Oros 2008; da Silva 2012; Kyrou
2012; Lewis 2006; Lorusso 2008; Rahman 2011; Sakhel 2007;
Shalev1995;Weiss 2010;Zreik 1999). Five studies (Claman 2004;
Martinez 1991a; Martinez 1991b; Schmidt-Sarosi 1995; Scott
1994) used a random number table, not further specified. Two
studies (Nikbakht 2012; Sharma 2011) reported a random assign-
ment without further specification.
Allocation concealment
Concealment of allocation was stated explicitly in six studies
(AboulGheit 2010; da Silva 2012; Lewis 2006; Lorusso 2008;
Weiss 2010; Zreik 1999). After additional information about al-
location had been received, seven other trials (Andrés-Oros 2008;
Claman 2004; Martinez 1991a; Martinez 1991b; Sakhel 2007;
Scott 1994; Shalev 1995) could be deemed at low risk of bias in
this domain. Concealment of allocation was done by the use of
sealed opaque envelopes or a third party (Figure 2; Figure 3). Two
studies (Nikbakht 2012; Sharma 2011) were deemed at high risk
of this bias. Concealment of allocation was done with sealed en-
velopes in the latter study.
Blinding
In two studies (Scott 1994; Shalev 1995) blinding was performed.
Scott and co-workers used blinding of the sonographer to min-
imise the risk of observer bias in determining if ovulation had
taken place after injection of hCG or GnRH-a. None of the trials
had details on blinded analysis of the results. All studies were rated
at low risk of bias with respect to blinding as we determined that
it was unlikely to influence our review outcomes.
Incomplete outcome data
Nine studies reported information on dropouts (Claman 2004; da
Silva 2012; Kyrou 2012; Lewis 2006; Martinez 1991a; Martinez
1991b; Weiss 2010; Zreik 1999). The number of dropouts varied
from 0% to 31%. Additional information on dropouts was re-
ceived from four studies (Andrés-Oros 2008; Sakhel 2007; Shalev
1995; Weiss 2010). The first study (Andrés-Oros 2008) reported
the dropping out of 18 couples who did not meet the criteria to
induce ovulation (too many follicles, or no follicles). The main
reason for dropout in the study of Weiss and co-workers was a
transfer to in vitro fertilisation (IVF) because of overstimulation.
The other five studies reported no dropouts.
Claman and co-workers stated that the most important reasons
for dropping out were a spontaneous LH surge or an inadequate
follicular response. Lewis and co-workers noted failure to detect
an LH surge in 23% of the participants in the LH group. In the
hCG group 5.3% of the participants dropped out due to personal
reasons, especially because of time commitment. An ITT analysis
was performed resulting in no significant difference between the
treatment groups. In the study of Zreik and co-workers only one
couple out of 54 was excluded, due to failure in compliance. None
of the included women in the studies by Martinez 1991b and
Kyrou 2012 dropped out. The other study of Martinez (Martinez
1991a) reported that five women decided to stop after the second
cycle, and five did not complete the third cycle. Finally, the study
of da Silva 2012 reported major protocol deviations in 117/635
couples, no hCG due to insufficient follicular growth in 61/635
couples, and serum estradiol (E2) > 1500 pg/ml or premature LH
peak (LH > 10 mIU/ml). No explanation for protocol deviation
was reported.
Selective reporting
A total of 44% of the included studies reported live birth rates.
The remaining studies defined clinical pregnancy rates (see table
Characteristics of included studies).
Other potential sources of bias
Sakhel and co-workers reported that the included women in the
u-hCG group had a greater mean duration of infertility than the r-
hCGgroup,whichmay have been a source of bias in this study.The
same applies to the study of AboulGheit 2010 where the couples
in the IUI 24 hours after hCG group had a longer mean duration
of infertility. Weiss and co-workers reported significantly more
miscarriages in the group with a time interval of 36 hours, and the
study of Kyrou and co-workers included a high percentage of non-
subfertile women. da Silva 2012 did not report the exact size of the
dominant follicles per group, which might have introduced bias.
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Finally, Sharma 2011 excluded 20 couples before randomisation
for unclear reasons.
Effects of interventions
See: Summary of findings for the main comparison hCG
compared to LH surge for intrauterine insemination in subfertile
couples; Summary of findings 2 u-hCG compared to r-hCG
for intrauterine insemination in subfertile couples; Summary
of findings 3 Short interval compared to long interval for
intrauterine insemination in subfertile couples; Summary
of findings 4 hCG compared to GnRH-a for intrauterine
insemination in subfertile couples; Summary of findings 5 Early
hCG compared to late hCG for intrauterine insemination in
subfertile couples; Summary of findings 6 Differing dosages of
hCG for intrauterine insemination in subfertile couples
Overall 18 studies with a total of 2279 couples were included in
the review.
1. hCG versus LH surge
Four studies compared hCG with LH surge for timing IUI (Lewis
2006; Martinez 1991a; Martinez 1991b; Zreik 1999).
1.1 Live birth rate
One study (Martinez 1991a) reported live birth rate. There was no
evidence of a difference between hCG and LH surge (odds ratio
(OR) 1.0, 95% confidence interval (CI) 0.06 to 18.08; 1 trial, 24
women, very low quality evidence) (Analysis 1.1).
1.2 Pregnancy rate
All trials included for this comparison reported pregnancy rate per
couple. The result revealed no evidence of a difference in pregnancy
rate per couple (OR 1.33, 95% CI 0.72 to 2.45; 4 trials, 275
women, I2 = 0%, low quality evidence) (Analysis 1.2, Figure 4).
Figure 4. Forest plot of comparison: 1 hCG versus LH surge, outcome: 1.2 pregnancy rate per couple.
1.3 Multiple pregnancy rate
The meta-analysis of two studies (Lewis 2006; Martinez 1991a)
revealed no evidence of a difference in multiple pregnancy rates
(OR 1.12, 95% CI 0.17 to 7.6; 2 trials, 42 pregnancies, very low
quality evidence) (Analysis 1.3).
2. u-hCG versus r-hCG
Two studies (Lorusso 2008; Sakhel 2007) compared u-hCG with
r-hCG for timing IUI.
2.1 Live birth rate
One study (Sakhel 2007) reported live birth rate, which showed
no evidence of a difference between u-hCG and r-hCG (OR 1.17,
95% CI 0.68 to 2.03; 1 trial, 284 women, low quality evidence)
(Analysis 2.1).
2.2 Pregnancy rate
All trials included in this comparison reported pregnancy rate per
couple. The result revealed no evidence of a difference in pregnancy
rate per couple (OR 1.02, 95% CI 0.65 to 1.57; 2 trials, 409
women, I2 = 0%, low quality evidence) (Analysis 2.2, Figure 5).
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Figure 5. Forest plot of comparison: 2 u-hCG versus r-hCG, outcome: 2.2 pregnancy rate per couple.
2.3 Multiple pregnancy rate
No evidence of a difference in multiple pregnancy rates was re-
ported (OR 0.99, 95% CI 0.4 to 2.47; 2 trials, 109 pregnancies,
low quality evidence) (Analysis 2.3).
2.4 Miscarriage rate
Miscarriages per treatment group showed no evidence of a differ-
ence between groups (OR 0.57, 95% CI 0.13 to 2.47; 2 trials,
109 pregnancies, I2 = 0%, very low quality evidence) (Analysis
2.4, Figure 6).
Figure 6. Forest plot of comparison: 2 u-hCG versus r-hCG, outcome: 2.4 miscarriage rate per pregnancy.
2.5 OHSS rate
Both studies reported no cases of (severe) OHSS in a total of 468
cycles (moderate quality evidence) (Analysis 2.5).
3. Short versus long interval
Two studies (AboulGheit 2010; Rahman 2011) compared a short
interval (24 hours) with a long interval (34 to 36 hours) after
hCG. AboulGheit 2010 included a third group (IUI 48 hours after
hCG).
3.1 Live birth rate
One study (Rahman 2011) reported live birth rate, which showed
no evidence of a difference between IUI after 24 hours and 34
hours (OR 0.52, 95% CI 0.27 to 1.00; 1 trial, 204 couples, low
quality evidence) (Analysis 3.1).
3.2 Pregnancy rate
Both studies reported pregnancy rate per couple. The meta-analy-
sis revealed a lower pregnancy rate in the 24 hour group, when IUI
was after 24 hours compared with IUI after 34 to 36 hours (OR
0.55, 95% CI 0.31 to 0.98; 2 trials, 234 women, I2 = 0%, low
quality evidence) (Analysis 3.2). AboulGheit 2010 also compared
IUI after 24 hours with IUI after 48 hours and found no evidence
of a difference between the groups (OR 0.44, 95% CI 0.10 to
1.92; 1 trial, 30 women, low quality evidence) (Analysis 3.2). Nor
was there a diffference between IUI after 34 to 36 hours and IUI
after 48 hours (OR 0.58, 95% CI 0.14 to 2.48; 1 trial, 30 women,
low quality evidence) (Analysis 3.2, Figure 7).
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Figure 7. Forest plot of comparison: 3 short versus long interval, outcome: 3.2 pregnancy rate per couple.
3.3 Miscarriage rate
Both studies reported miscarriage rates, with no evidence of a
difference between the groups of 24 hours versus 34 to 36 hours
(OR 1.58, 95% CI 0.35 to 7.16; 2 trials, 67 pregnancies, I2 =
0%, very low quality evidence); 24 hours versus 48 hours (OR
4.0, 95% CI 0.27 to 58.56; 1 trial, 15 women, very low quality
evidence); 34 to 36 hours versus 48 hours (OR 1.33, 95% CI
0.07 to 25.91; 1 trial, 16 women, very low quality evidence) (
Analysis 3.3) respectively. Two studies (Claman 2004;Weiss 2010)
were excluded from the meta-analysis since they reported results
as pregnancy rates per cycle only. The former did not report a
difference between 32 to 34 hours and 38 to 40 hours after hCG,
and the latter studywas stoppedprematurely because of an unusual
number of multi-fetal pregnancies; the study reported a higher
pregnancy rate for 42 hours after hCG compared to 36 hours or
48 hours (see table ’Characteristics of included studies’ for details,
Figure 8).
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Figure 8. Forest plot of comparison: 3 short versus long interval, outcome: 3.3 miscarriage rate per
pregnancy.
4. hCG versus GnRH-a
Four studies (Andrés-Oros 2008; Schmidt-Sarosi 1995; Scott
1994; Shalev 1995) compared hCG versus GnRH-a.
4.1 Live birth rate
The results for live birth rate per couple revealed no evidence of a
difference between the groups (OR 1.04, 95% CI 0.42 to 2.56; 3
trials, 104 women, I2 = 0%, low quality evidence) (Analysis 4.1,
Figure 9).
Figure 9. Forest plot of comparison: 4 hCG versus GnRH-a, outcome: 4.1 live birth rate per couple.
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4.2 Pregnancy rate
All trials reported the pregnancy rate per couple revealing no ev-
idence of a difference between groups (OR 1.14, 95% CI 0.63
to 2.08; 4 trials, 206 women, I2 = 48%, low quality evidence)
(Analysis 4.2, Figure 10).
Figure 10. Forest plot of comparison: 4 hCG versus GnRH-a, outcome: 4.2 pregnancy rate per couple.
4.3 Multiple pregnancy rate
The studies reported three twin pregnancies in the GnRH-a group
and none in the hCG group. There was no evidence of a difference
inmultiple pregnancy rates between hCGandGnRH-a (OR0.15,
95% CI 0.02 to 1.38; 4 trials, 74 pregnancies, I2 = 0%, very low
quality evidence) (Analysis 4.3, Figure 11).
Figure 11. Forest plot of comparison: 4 hCG versus GnRH-a, outcome: 4.3 multiple pregnancy rate per
pregnancy.
4.4 Miscarriage rate
There was no evidence of a difference in the miscarriage rate be-
tween the GnRH-a and hCG group (OR 1.72, 95% CI 0.48 to
6.2; 4 trials, 74 pregnancies, I2 = 0%, very low quality evidence)
(Analysis 4.4, Figure 12).
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Figure 12. Forest plot of comparison: 4 hCG versus GnRH-a, outcome: 4.4 miscarriage rate per pregnancy.
4.5 OHSS rate
OHSS rates were compared and there was no evidence of a dif-
ference between groups (OR 2.27, 95% CI 0.65 to 7.91; 3 trials,
456 women, low quality evidence) (Analysis 4.5). Shalev 1995 re-
ported four treatment cycles with grade three to grade four OHSS
in the GnRH-a group, and eight treatment cycles with OHSS in
the hCG group; the other two studies in this meta-analysis re-
ported none in either group.
5. Early versus late hCG
One study (da Silva 2012) compared early hCG versus late hCG.
5.1 Pregnancy rate
No evidence of a difference was reported between both treatment
groups in the pregnancy rate per couple (OR 1.32, 95% CI 0.77
to 2.25; 1 trial, 612 women, low quality evidence) (Analysis 5.1).
5.2 Miscarriage rate
No evidence of a difference between miscarriages rates was re-
ported (OR 0.51, 95% CI 0.08 to 3.28; 1 trial, 65 pregnancies,
very low quality evidence) (Analysis 5.2).
The authors reported two multiple pregnancies in the early hCG
group and none in the late hCG group.
6. Different dosages of hCG
One trial (Nikbakht 2012) compared 250 ug r-hCG with 500 ug
r-hCG.
6.1 Pregnancy rate
No evidence of a difference in pregnancy rate per couple was re-
ported (OR 1.38, 95% CI 0.28 to 6.71; 1 trial, 66 women, very
low quality evidence) (Analysis 6.1).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
u-hCG compared to r-hCG for intrauterine insemination in subfertile couples
Population: women undergoing intrauterine insemination
Intervention: u-hCG
Comparison: r-hCG




Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
R-hCG U-hCG








Pregnancy rate per cou-
ple
































There were no events in
either study
*The basis for the assumed risk was the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison
group and the relative effect of the intervention (and its 95% CI).








































































































GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Methods used for random sequence generation and/or allocation concealment were unclear.
2There was serious imprecision: findings were compatible with substantial benefit in either group, or with no effect.
3One study did not report the method of allocation concealment used.









































































































Short interval compared to long interval for intrauterine insemination in subfertile couples
Population: women undergoing intrauterine insemination
Intervention: short interval
Comparison: long interval




Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Long interval Short interval
Live birth rate per couple
- 24 hours versus 34 to
36 hours








Pregnancy rate per cou-
ple - 24 hours versus 34
to 36 hours








Pregnancy rate per cou-
ple - 24 hours versus 48
hours








Pregnancy rate per cou-
ple - 34 to 36 hours ver-
sus 48 hours









pregnancy - 24 hours
versus 34 to 36 hours









pregnancy - 24 hours
versus 48 hours
















































































































pregnancy - 34 to 36
hours versus 48 hours








*The basis for the assumed risk was the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison
group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Methods used for random sequence generation or allocation concealment were unclear.
2There was serious imprecision: findings were compatible with substantial benefit in the long interval group, or with no effect. (See
comment)








































































































hCG compared to GnRH-a for intrauterine insemination in subfertile couples
Population: women undergoing intrauterine insemination
Intervention: hCG
Comparison: GnRH-a




Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
GnRH-a HCG








Pregnancy rate per cou-
ple




































*The basis for the assumed risk was the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison
group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.






































































































1Methods used for random sequence generation and allocation concealment were unclear.
2There was serious imprecision: findings were compatible with substantial benefit in either group, or with no effect.









































































































Early hCG compared to late hCG for intrauterine insemination in subfertile couples
Population: women undergoing intrauterine insemination
Intervention: Early hCG
Comparison: Late hCG




Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Late hCG Early hCG
Pregnancy rate per cou-
ple
















*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Unclear risk of attrition bias.
2There was serious imprecision: findings were compatible with substantial benefit in the early hCG group, or with no effect.








































































































Differing dosages of hCG for intrauterine insemination in subfertile couples
Population: women undergoing intrauterine insemination
Intervention: differing dosages of hCG: 500 µg hCG versus 250 µg hCG




Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
250 µg hCG 500 µg hCG
Pregnancy rate per cou-
ple








*The basis for the assumed risk was the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison
group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Methods of random sequence generation and allocation concealment were unclear, high risk of attrition bias.








































































































D I S C U S S I O N
Summary of main results
The aim of this review was to investigate the optimal synchroni-
sation of ovulation with intrauterine insemination (IUI) in sub-
fertile couples undergoing natural and stimulated cycles with re-
gard to live birth rates. The trials in this review revealed that not
one of the available methods is superior to another. However, the
available evidence is scarce due to small sample sizes and lack of
data concerning the primary outcome.
hCG injection versus LH surge detection
Although the dropout rate in the LH surge group was much higher
than in the hCG group (due to no detection of a LH surge in 23%
of the cycles) there was no evidence of a difference in live birth
or pregnancy rates between these treatment groups (OR 1.5, 95%
CI 0.73 to 3.1) (Lewis 2006).
The cause of dropouts in the LH surge group could be the absence
of detection of LH surges in urine samples. This has been reported
in other studies as well, due to a short LH surge or incorrect use of
the intervention by the woman (Miller 1996). When counselling
couples, the advantages of home ovulation predictor tests (no dif-
ference in pregnancy outcomes compared to hCG injection, con-
venience and low costs) and disadvantages (high number of false-
negative results) should be considered in relationship to the advan-
tages (low number of false-negative results) and disadvantages (ex-
pensive and time consuming) of ultrasound detection combined
with hCG injection. No data on the occurrences of premature LH
surges in the hCG group have been reported in the pooled stud-
ies. This might negatively influence the treatment outcome in the
hCG group, resulting in lower pregnancy rates and no percepti-
ble difference between timing using LH surge detection and hCG
injection (Cantineau 2007).
The general quality of the evidence was estimated to be low or
very low, meaning that further research is likely or very likely to
have an important impact on our confidence in the estimate of
effect and is likely to change this estimate (Summary of findings
for the main comparison).
Urinary hCG (u-hCG) versus recombinant hCG (r-hCG)
No evidence of a difference in pregnancy rates was found between
u-hCG and r-hCG. Other reasons such as costs, injection site
reactions and possible batch-to-batch inconsistencies should be
considered in deciding which to use.
The general quality of the evidence was estimated to be low or
very low (Summary of findings 2).
Short (24 hours) versus long interval (36 hours)
The evidence provided by prospective studies (AboulGheit 2010;
Rahman 2011) comparing different hCG to IUI intervals after
ovarian stimulation revealedmore live birthswhen an interval of 34
to 36 hours was used. However, this difference was not statistically
significant. A higher number of pregnancies was reported when
IUI was performed 34 to 36 hours after hCG compared to IUI
24 hours after hCG injection. This might be in part due to a
significant difference in the duration of subfertility (significantly
longer in the 24 hours group in the study of AboulGheit 2010).
This study and other studies that only reported pregnancy rate per
cycle suggest a more flexible approach in timing IUI after hCG,
which allows women to inject hCG in the early evening when
pharmacies are still open, in case of problems (Claman 2004).
The general quality of the evidence was estimated to be low or
very low (Summary of findings 3).
hCG versus GnRH agonist (GnRH-a)
No evidence of a difference was found, when analysing live birth
rates and pregnancy rates, between the timingmethods using hCG
and GnRH-a. More evidence is needed to determine the place of
GnRH-a as a timing method for IUI, also considering costs and
secondary outcomes such as the OHSS rate.
The general quality of the evidence was estimated to be low or
very low (Summary of findings 4).
Early hCG versus late hCG depending on the size of the
dominant follicle
As well as the ITT analysis, the per protocol analysis reported no
advantage of hCG injection with a dominant follicle between 16.0
and 16.9 mm compared to a dominant follicle between 18.0 and
18.9 mm (da Silva 2012). Significantly more dominant follicles
and significantly higher estradiol levels were seen in the late group
without significantly increased numbers of premature LH surges
or clinical pregnancies. No information was reported on the exact
sizes of the dominant follicles. For example, when a dominant
follicle was 17 mm in the early group it was unclear whether it
was stated as a major protocol deviation. Since the day of hCG
administration and the total dose of HMG did not differ, it is
questionable how different the groups really were.
The general quality of the evidence was estimated to be low or
very low (Summary of findings 5).
Different dosages of hCG
No evidence of a difference was found between 250 µg r-hCG and
500 µg r-hCG. Significantly more dominant follicles were seen in
the 250 µg r-hCG group, which might be a confounding factor.
The quality of the evidence overall was estimated to be low or very
low (Summary of findings 6).
Overall completeness and applicability of
evidence
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Definite answers could not be given for most comparisons. When
performing IUI, small numbers show a positive effect of insemi-
nation around 34 to 36 hours compared to 24 hours after hCG
injection.
Quality of the evidence
The quality of the evidence for most comparisons was low or very
low. The main limitations in the evidence were failure to describe
study methods, serious imprecision and attrition bias.
Potential biases in the review process
Our searches aimed to identify all potentially eligible studies.
Agreements and disagreements with other
studies or reviews
Noother reviews were available concerning the difference between
hCG injection and the LH detection test for timing IUI. Other
retrospective studies revealed conflicting results.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is insufficient evidence to determine whether different
methods of synchronization of ovulation and insemination differ
in safety and effectiveness. More research is needed.
There is no evidence to advise one of the treatment options over
another (ultrasound combined with hCG injection versus urinary
LH surge detection, medication to time the insemination, dose of
medication, time interval between medication and insemination)
since live births and pregnancy rates do not differ significantly.
The choice should be based on hospital facilities, convenience for
the couple, medical staff, costs and dropout levels.
The choice of urinary hCG or recombinant hCG should be based
on costs and couples’ preferences since pregnancy rates are not
significantly different.
Since the evidence suggested an advantage of insemination 34
to 36 hours after hCG, this could be advised until more reliable
evidence is available from well-powered RCTs.
The results suggest that no advice could be given on the timing of
hCG injection in relationship to the size of the dominant follicles
nor on the dosages of recombinant hCG.
Implications for research
Large prospective multi-centre trials with adequate concealment
of allocation comparing ultrasound monitoring combined with
hCG injection and LH surge detection in urinary samples should
be performed with special attention to costs and the convenience
of the treatments.
Large prospective multi-centre trials with adequate concealment
of allocation and comparing different time intervals between hCG
and IUI should be performed, with special attention to conve-
nience for the patient. Data should be adequately reported as the
live birth rate per couple or at least as the ongoing pregnancy rate
per couple. Adverse effects should also be reported.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
AboulGheit 2010
Methods Single centre, parallel prospective randomised trial. Concealment of allocation: third
party
Blinding not stated. Follow up not stated. Duration study: January 2008 to July 2009
Power calculation not stated.
Participants 45 couples, 125 cycles, duration of subfertility not stated
Exclusion criteria: couples with bilateral tubal block and women with endocrinological
disorders
Mean age of women, 24 h after hCG: 28.7 yrs ± 6.1, 34 h after hCG: 26.4 ± 4.5 and 48
h after hCG: 26.8 yrs ± 4.3
Type of subfertility: unexplained
Interventions IUI 24 hours, 34 hours or 48 hours after hCG
Stimulation method: was not stated except 10.000 IU hCG when the leading follicle
reached ≥ 18 mm and at least two follicles reached ≥ 16 mm
Type of semen: partner semen. Semen prepared with a swim up technique
Insemination procedure: IUI catheter, one insemination per cycle
Outcomes Clinical pregnancy rate per couple: 24 h group 6/15 (40%), 34 h group 7/15 (46%), 48
h group 9/15 (60%)
Clinical pregnancy defined as gestational sac and later evidence of fetal heart activity on
transvaginal ultrasound
Notes Method of randomisation unclear. Signifcantly different in mean of subfertility between
treatment groups
Duration of subfertility was significantly longer in the group where IUI was performed
after 24 hours
The author did not have an explanation for this difference
Setting: Obstetric and Gynaecology Department Cairo University, Egypt
Funding not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information about sequence
generation
Allocation concealment (selection bias) Low risk Coupleswere randomised into three groups
by a third party (nurse)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding stated, but outcome is not
likely to be influenced
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AboulGheit 2010 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding stated, but outcome is not
likely to be influenced
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias Low risk No other bias
Andrés-Oros 2008
Methods Single centre, parallel prospective randomised trial. Computer generated list of random
numbers. Concealment of allocation: third party
Blinding not stated. Follow up not stated. Duration study not stated
Power calculation not stated
Participants 120 couples, 290 cycles, at least 2 years of subfertility
Exclusion criteria: women with PCOS or other cycle disturbances, semen analysis < 5
million after work up
Mean age of women: r-hCG group: 32.2 yrs ± 2.5 and GnRH-a group: 32.3 yrs ± 2.5
Type of subfertility: unexplained, endometriosis stage 1 or 2, male factor (WHO 1992)
, unilateral tubal factor
Interventions GnRH-a versus r-hCG for triggering ovulation in IUI
Stimulation method: 75 IU FSH, 250 ug r-hCG sc or 0.2 mg GnRH-a sc (triptorelin
0.2 mg)
IUI 36 hours after injection of hCG or GnRH-a
Type of semen not explicitly stated. Semen prepared with a swim up technique
Insemination procedure: Gynetics catheter, one insemination per cycle
Outcomes Clinical pregnancy rate per couple: r-hCG group 21/60 (35%), GnRH-a group 15/42
(35.7%)
Number of miscarriages: r-hCG group 3/21 (14%), GnRH-a group 1/15 (6.7%)
Multiple pregnancy rates: r-hCG group 0/21 (0%), GnRH-a group 1/15 (6.7%)
Pregnancy diagnosed: transvaginal ultrasound demonstrating heart activity
Notes 60 couples received r-hCG and only 42 couples received GnRH-a. The other 18 couples
did not reach the point to induce ovulation due to too many, or no follicles. The author
did not have an explanation for this difference




Bias Authors’ judgement Support for judgement
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Andrés-Oros 2008 (Continued)
Random sequence generation (selection
bias)
Low risk A computer generated list of random num-
bers
Allocation concealment (selection bias) Unclear risk None stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding stated, outcome not likely to
be influenced
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding stated, outcome not likely to
be influenced
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias Low risk No other bias
Claman 2004
Methods Single centre, parallel design with random number table. Concealment of allocation:
third party
No blinding used. Duration of the study and follow up not stated
Power calculation: sample size of 190 with a power of 0.8 to detect an increase in
pregnancy rate from 15% to 30% between groups with an alpha of 0.05. ITT: no
Participants 75 women, 189 cycles, > 2 years subfertility
Exclusion criteria: cycles with endogenous LH surge
Mean age of women: short hCG-IUI interval: 34.4 yrs ± 3.6 and long hCG-IUI interval:
34.3 yrs ± 3.6
Type of subfertility: unexplained, endometriosis stage 1 or 2, male factor (WHO 1992)
, clomiphene resistant oligo-ovulation, or combination of factors
Interventions Stimulation method: 100 to 225 IU FSH, 5000 IU hCG im or 10,000 IU hCG sc
IUI either 32 to 34 hours or 38 to 40 hours after injection of hCG
Type of semen not explicitly stated. Semen prepared with a two-layer density gradient
separation technique, final sample suspended in 0.35 ml of culture medium
Insemination procedure: Tomcat catheter high up in the uterine fundus, one insemina-
tion per cycle
Outcomes Pregnancy rate per cycle: short interval 20/96 (20%), long interval group 14/93 (15%)
Secondary outcomes not stated
Pregnancy diagnosed: transvaginal ultrasound demonstrating heart activity
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Claman 2004 (Continued)
Notes Inclusion of couples with oligo-ovulation
Setting: Division of Reproductive Medicine, Department of Obstetrics and Gynecology,
The Ottawa Hospital, Canada
No funding
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk None stated; the author comment ‘next
random number in the table’ does not state
the random sequence generation
Allocation concealment (selection bias) Low risk Third party (a nurse) in the clinical care
team picked the next random number in
the table and crossed it
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
Incomplete outcome data (attrition bias)
All outcomes
Low risk Incomplete outcome data addressed ade-
quately
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias Low risk No other bias
da Silva 2012
Methods Multi-centre trial, parallel design with automatically generated randomisation. Conceal-
ment of allocation: third party (centralised telephonic system). Blinding was not stated.
Duration of the study 3 years
Power calculation: sample size of 260 in each group with a power of 0.8. ITT: stated,
Per protocol group stated separately
Participants 635 women, cycles not stated, 2 to 5 years of subfertility
Exclusion criteria: tubal obstruction, endometriosis grade III and IV, metrorrhagia of
unknown origin, present or past malignant or metabolic or endocrine diseases, cervical
infection, positive serology for hepatitis B, C, HIV or syphilis, anti-spermatozoa anti-
bodies, positive sperm culture, ejaculation disorders, alcohol or drug addiction, partici-
pation in another clinical trial in the previous month. Occurence of a spontaneous LH
surge during COS before the day of hCG administration
Mean age of women: early hCG: 30.9 yrs ± 3.8 and late hCG: 31.0 yrs ± 3.8
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da Silva 2012 (Continued)
Type of subfertility: unexplained, endometriosis stage 1 or 2, male factor, female factor
or combination of factors
Interventions Stimulation method: 75 IU FSH/day from day 4 (maximum dose 300 IU), 5000 IU
hCG im
IUI 36 hours after injection of hCG. hCG when DF 16.0 to 16.9 mm or within 18.0
to 18.9 mm
Type of semen: husband. Semen prepared with double centrifugation technique using
standardized protocols
Insemination procedure: not stated. Luteal support with progesterone vaginally
Outcomes Clinical pregnancy rate: early 36/309 (11.7%), late group 29/303 (9.6%)
Secondary outcomes: ongoing intrauterine pregnancy rate (>10 weeks) and incidence of
premature LH surge before hCG administration
Pregnancy diagnosed: transvaginal ultrasound demonstrating heart activity
Notes 117 major protocol deviations
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Groups of randomisation were automat-
ically generated using a centralized tele-
phonic system
Allocation concealment (selection bias) Low risk The use of a centralized telephonic system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Only states ’treatment not initiated in 23
participants’, does not state reason
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias Low risk No other bias
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Kyrou 2012
Methods Single centre, parallel design with randomisation on the basis of a computer generated
list. Concealment of allocation: not stated
No blinding used. Duration of the study: April 2009 until October 2010. Duration of
follow up not stated
Power calculation: sample size of 2943 couples in each group to achieve 80% power of
at a 5% significance level to detect a difference of 3%. No ITT
Participants 300 women, 300 cycles
Inclusion criteria: age ≤ 36 years, regular menstrual cycles, BMI between 18 and 29 kg/
m2, basal concentration of FSH (≤ 12 IU/L), estradiol (≤ 80 pg/ml) and progesterone
(≤ 1.6 ng/ml) on cycle day 1 and normal hysterosalpingography. Husband semen with
more than 5 million spermatozoa per ejaculation and morphology > 4% normal. Donor
semen
Exclusion criteria: PCO and endometriosis
Mean age of women: LH surge group: 31.5 ± 3.7 yrs, and hCG group: 31.4 ± 3.7 yrs
Mean duration of subfertility not stated
Type of subfertility: unexplained, male factor
Interventions Stimulation method: natural cycle
LH surge group: daily serum testing of LH from cycle day 6. hCG group: 10,000 IU
hCG at follicle size of ≥ 17mm. IUI 24 to 36 hours later
Husband semen and donor semen
Insemination procedure: 0.3 ml of semen into the uterine cavity through a Friedman
catheter, bed rest for 10 min. One insemination
Outcomes Pregnancy rate per couple: LH surge group 34/150 (22.7%) and hCG group 16/150
(10.7%)
Secondary outcome measures: not stated
Costs: not stated
Pregnancy diagnosed: ultrasound at 12 weeks gestation
Notes Large group without subfertility (lesbian couples, single mother); LH group 58%, hCG
group 58.7%
Setting: Centre for Reproductive Medicine, University Hospital Brussels, Belgium
No funding stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised on the basis
of a computer generated list
Allocation concealment (selection bias) Unclear risk None stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
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Kyrou 2012 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias High risk Comment: high percentage of non-subfer-
tile women included
Lewis 2006
Methods Single centre, parallel design. Randomisation order was assigned by computer program
Blinding until first ultrasound after informed consent. Duration of the study and follow
up not stated
Power calculation: a sample size of 75 women in each group was needed to detect
differences in cumulative pregnancy rates of 22% versus 49% after 3 cycles. ITT was
performed
Participants 150 women, 129 completed at least one cycle
Inclusion criteria: > 1 year subfertility or three failed cycles of donor IUI. At least one
patent tube and a functional ipsilateral ovary. Four million motile spermatozoa with
normal morphology
Exclusion criteria: elevated FSH levels on cycle day 3, severe endometriosis, recurrent
pregnancy loss, previous use of superovulation and IUI
Age of women: LH surge group: 33.5 ± 3.9 yrs and hCG group: 34.0 ± 3.9 yrs
Type of subfertility: unexplained, mild endometriosis, male factor, cervical factor, tubal
or pelvic factor
Interventions Stimulation method: 100 mg clomiphene citrate from day 5 through day 9
LH surge group: home monitoring u-LH and IUI morning after positive test. hCG
group: 10,000 IU hCG and IUI 33 to 42 hours later
Husband semen and probably donor semen
Insemination procedure: not stated. One insemination per cycle
Outcomes Pregnancy rate per couple: LH surge group 25% and hCG group: 31%
Multiple pregnancy rate per couple: LH surge group 11.1% and hCG group: 12.9%.
Miscarriage rate per couple: LH surge group: 34% and hCG group: 18%
Costs: stated in the abstract. Cost per pregnancyLHgroupUSD3695; cost per pregnancy
hCG group USD 4830
Pregnancy diagnosed: rising concentration of hCG. Viable pregnancy is defined as a fetal
pole with heart activity by ultrasound
Notes The abstract used different pregnancy rates as did the full text article
Setting: Department of Obstetrics and Gynecology, University of Rochester School of
Medicine and Dentistry, Rochester, New York, USA
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Lewis 2006 (Continued)
Funding by product donation by Serono, Inc, Rockland, Massachusetts
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation order was assigned by com-
puter program
Allocation concealment (selection bias) Unclear risk Only states ‘Treatment group assignment
was not known’, but method of conceal-
ment is not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
Incomplete outcome data (attrition bias)
All outcomes
High risk Reason of missing data not stated; im-
balance in numbers across intervention
groups, possibly related to true outcome
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias Low risk No other bias
Lorusso 2008
Methods Single centre, parallel design for three cycles. Randomisation order was assigned by
computer generated table. Concealment of allocation: sealed opaque envelopes
Blinding unclear. Follow up until pregnancy was beyond 12th week of gestation. Power
calculation: at least 61 couples in each group would be required to achieve 80% power
to detect an increase of 20% in progesterone levels in the r-hCG group. ITT was not
stated
Duration: IUI treatment between October 2005 and December 2007
Participants 125 women, 184 cycles were completed
Inclusion criteria: endometriosis grade I or II according to the AFS, infertility due to
sexual dysfunction, a normal uterine cavity and tubal patency assessed by HSG and/or
laparoscopy, primary or secondary infertility lasting for at least 24 months, no infection
of semen in last 6 months, normal semen analysis according to the WHO or at least
5 million motile spermatozoa after semen preparation, willingness to participate in the
study and to comply with the procedure
Exclusion criteria: maternal age > 40 years, severe male-factor infertility, endometriosis
grade III or IV, previous IVF attempts, positive hepatitis B virus, hepatitis C virus or
HIV serology, PCOS or recurrent miscarriage
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Lorusso 2008 (Continued)
Age of women: r-hCG group: 33 ± 3.6 yrs and u-hCG group: 32.0 ± 4.4 yrs
Duration of subfertility: r-hCG group: 4 ± 1.7 yrs and u-hCG group: 3 ± 2.4 yrs
Type of subfertility: mild endometriosis, mild male factor, unexplained infertility
Interventions Stimulation method: daily dose of 37.5 IU r-FSH starting from cycle day 2 to 3 for 5
days according to a low-dose, step up protocol
250 µg sc r-hCG or 5000 IU u-hCG IM when one follicle with mean diameter > 17
mm was present and no more than 3 follicles with a mean diameter > 15 mm IUI was
carried out 24 hr and 48 hr after hCG administration
Husband’s semen
Insemination procedure: not stated; two inseminations
Outcomes Pregnancy rate per couple: r-hCG group 29.7% and u-hCG group: 24.6%
Clinical pregnancy rate per couple: r-hCG group: 25% and u-hCG group: 22.9%
Multiple pregnancy rate per couple: none. Miscarriage rate per pregnancy: r-hCG group:
6.3% and u-hCG group: 7.1%
Costs: not stated
Pregnancy diagnosed: serum hCG testing 14 days after IUI. Clinical pregnancy was
defined as fetal cardiac activity on transvaginal sonography
Notes Primary endpoint was the ovulation rate
Setting: Centre for Physiopathology of Human Reproduction and Gametes Cryopreser-
vation, Gynaecology and Obstetrics, University of Bari, Italy
No funding
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Couples were randomised by a computer
generated table
Allocation concealment (selection bias) Low risk Concealment by use of sealed opaque en-
velopes, each containing a unique study
number and prepared independently by a
secretary
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data
Selective reporting (reporting bias) Unclear risk No protocol available
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Lorusso 2008 (Continued)
Other bias Low risk No other bias
Martinez 1991a
Methods Single centre, cross-over. Random number table, sealed envelopes
Blinding not stated. Follow up not stated. Power calculation not stated. ITT not stated
Duration: trial was conducted between January and November 1990
Participants 12 women, 12 cycles (we only used pre-cross over first cycle data). Total study group: 48
women, 160 cycles
Inclusion criteria: male subfertility or unexplained infertility
Exclusion criteria: not stated
Mean age for the total group of 48 women: 33 ± 2.9 yrs
Mean duration of subfertility for the subfertility for the total group of 48 women: 6.3 ±
2.8 yrs
Type of subfertility: male or idiopathic
Interventions Stimulation method: 75 to 150 IU HMG IM
LH surge group: u-LH detection kit two times a day, IUI 16 to 28 hours after a positive
test. hCG group; 10,000 IU hCG, IUI after 36 to 40 hours
Husband semen. Semen prepared with a two-layer Percoll gradient centrifugation, final
sample suspended in 0.2 ml of culture media
Insemination procedure: 0.5 cm from the uterine fundus with the use of a Makler’s
device, one insemination
Outcomes Live birth rate: LH group 17%, hCG group 17%
Clinical pregnancy rate: LH group: 17% , hCG group: 17%
No secondary outcomes stated: no multiple pregnancies, no miscarriages, no costs
Pregnancy diagnosed: hCG in urine 14 days after IUI
Notes This study also compares IUI to timed intercourse. Because of the double comparison
and the cross-over design, we only used the pre-cross over IUI data
Setting: Department of Reproductive Endocrinology and Fertility, Free University Hos-
pital, Amsterdam, the Netherlands
Funding: supported by Organon International, Oss, the Netherlands
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk None stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
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Martinez 1991a (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
Incomplete outcome data (attrition bias)
All outcomes
Low risk Incomplete data adequately addressed, no
imbalance
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias Low risk No other bias
Martinez 1991b
Methods Single centre, cross-over. Random number table, sealed opaque envelopes
Blinding not stated. Follow up not stated. Power calculation not stated. No ITT
Study duration not stated
Participants 48 women, 48 first cycles
Inclusion criteria: idiopathic, male or cervical factor infertility
Exclusion criteria: not stated.
Mean age of women: 31.2 ± 3.8 yrs for the total group of women
Mean duration of subfertility: 5.6 ± 2.6 yrs
Type of subfertility: idiopathic, male or cervical factor infertility
Interventions Stimulation method: 100 mg clomiphene citrate from day three through day seven
LH group; home monitoring u-LH and IUI 21 to 24 hours after a positive test. hCG
group: 10,000 IU hCG and IUI 37 to 40 hours later
Husband semen. Semen prepared with a Percoll density gradient centrifugation, final
sample suspended in 0,2 ml of culture media
Insemination procedure: 0.5 cm from the uterine fundus with the use of a Makler’s
device, one insemination
Outcomes Live birth rate: 21% LH group, 17% hCG group
Pregnancy rate: 21% LH group, 17% hCG group
Multiple pregnancy rate: not known in the LH group, 25% hCG group
Costs: not stated
Pregnancy diagnosed: hCG in urine 14 days after IUI
Notes Only the first cycle pre-cross over data were used
Setting: Department of Reproductive Endocrinology and Fertility, Free University Hos-
pital, Amsterdam, the Netherlands
Funding: Organon International, Oss, the Netherlands
Risk of bias
Bias Authors’ judgement Support for judgement
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Martinez 1991b (Continued)
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Author comment: ’sealed opaque en-
velopes’, does not state numbered
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias Low risk No other bias
Nikbakht 2012
Methods Single centre, randomised controlled clinical trial
Randomisation method and concealment of allocation not stated
Blinding not stated. Follow up until 6 weeks pregnancy. Power calculation: not stated
Study duration June 2009 to April 2010
Participants 66 women, number of cycles not stated
Inclusion criteria: healthy women age 22 to 44 years with > 1 year of non-tubal infertility
Exclusion criteria: not stated
Mean age of women: 28.5 ± 3 yrs (250 µg hCG) versus 31.9 ± 3 yrs (500 µg hCG)
Mean duration of subfertility: 5.0 ± 4.6 yrs (250 µg hCG) versus 6.9 ± 6.8 yrs (500 µg
hCG)
Interventions Stimulation method: clomiphene citrate or letrozole and HMG
Ovulation trigger: r-hCG 250 µg or 500 µg
Type of semen not stated explicitly, with swim up method
Insemination procedure: 0.3ml inseminated, catheter type not stated. One insemination
No luteal support was not stated
Outcomes Pregnancy rate per cycle: 9.9% (250 µg) versus 12.1% (500 µg)
Pregnancy diagnosed by vaginal ultrasound 4 weeks after IUI
Notes Setting: Ahvaz, Iran
In group with 250 µg hCG significantly more dominant follicles
Funding: research grant from the Ahvaz Jundishapur University of Medical Sciences
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Nikbakht 2012 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk None stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
Incomplete outcome data (attrition bias)
All outcomes
High risk States 66 women were randomly assigned
to one of two groups at the start of the
cycle and that 20 of the women refused to
participate to the study; still there are data
on 66 participants
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias Low risk No other bias
Rahman 2011
Methods Single centre, parallel design. Computer generated random tables
Concealment of allocation not stated
Blinding not stated. Follow up until delivery. Power calculation: 80 per group was pro-
posed to provide 80% power for the primary comparison of pregnancy rates
Study duration not stated
Participants 204 women, 461 first cycles
Inclusion criteria: idiopathic, mild male factor infertility
Exclusion criteria: severe male factor, women > 38 years, PCOS, endometriosis or tubal
disease
Mean age of women: 28.3 ± 3.2 yrs (36 h after hCG) versus 27.1 ± 2.3 yrs (24 h after
hCG)
Mean duration of subfertility: 4.5 ± 1.0 yrs (36 h after hCG) versus 4.3 ± 1.5 yrs (24 h
after hCG)
Type of subfertility: idiopathic, male or cervical factor infertility
Interventions Stimulation method: 50 mg clomiphene citrate from day three through day seven
Ovulation trigger: hCG 5000 IU, 24 hours or 36 hours later IUI
Husband semen. Semen prepared with a density gradient centrifugation
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Rahman 2011 (Continued)
Insemination procedure: flexible intrauterine catheter, one insemination
No luteal support
Outcomes Live birth rate per couple: 31/104 (29.8%) 36 h after hCG, 18/100 (18%) 24 h after
hCG
Pregnancy rate per cycle: 34/231 (14.7%) 36 h after hCG, 20/230 (8.7%) 24 h after
hCG
Pregnancy rate per couple: 34/104 (32.7%) 36 h after hCG, 20/100 (20%) 24 h after
hCG
Pregnancy diagnosed: transvaginal ultrasound demonstrating heart activity




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The use of computer generated random ta-
bles
Allocation concealment (selection bias) Unclear risk None stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias Low risk No other bias
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Sakhel 2007
Methods Single centre, parallel. Randomly assigned by computer generated numbers, sealed en-
velopes
Blinding not stated. Follow up: not clearly stated. Power calculation: performed after-
wards, a power of 63% was achieved. ITT was not performed since no dropouts or cycle
cancellations were reported
Duration: April 2003 to March 2004
Participants 284 women, 284 cycles
Inclusion criteria: healthy women between 22 and 44 years with non-tubal infertility.
One fallopian tube should be patent, unexplained subfertility, ovulatory disorder, mild to
moderate male factor, early stages of endometriosis and advanced stages of endometriosis
after conservative operative laparoscopy
Exclusion criteria: tubal blockage and severe male factor
Mean age of women: r-hCG group: 31.9 ± 4.1 yrs and u-hCG group: 32.7 ± 4.8 yrs
Duration of subfertility: r-hCG group: 2.3 ± 1.5 yrs and u-hCG group: 3.0 ± 2.3 yrs
Type of subfertility: ovulatory disorders, early stage endometriosis, mild male factor,
idiopathic infertility. Primary infertility in 55.8% of couples
Interventions Stimulation method: 75 to 150 IU FSH and HMG, GnRH antagonist
IUI 42 hours after injection of 10,000 IU u-hCG or 250 µg r-hCG
Type of semen injected: husband. Semen washed using the double-density gradient
method. Insemination of 0.3 ml
Insemination procedure: not stated, one insemination
Outcomes Outcome live birth rate per couple: 22.1% r-hCG, 25% u-hCG
Pregnancy rate per couple: 27.1% r-HCG, 28.5% u-hCG
Multiple pregnancy rate per cycle: 36.8% r-hCG, 36.6% u-hCG
Miscarriage rate per cycle: 10.5% r-hCG, 4.9% u-hCG
OHSS rate: no cases of severe OHSS
Ectopic pregnancy rate per cycle: 7.9% r-hCG, 7.3% u-hCG
Costs: not stated
Pregnancy diagnosed: serum hCG level two weeks after the insemination
Notes Aggressive stimulation with a mean number of ovulated follicles of 2.3 ± 1.4 r-hCG
group and 3.0 ± 2.0 u-hCG group, resulting in a high pregnancy andmultiple pregnancy
rate
Setting: IVF Michigan PC, Rochester Hills, MI, USA
Funding: supported in part by Serono, Rockland, Massachusetts
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly assigned by
computer generated numbers
Allocation concealment (selection bias) Unclear risk None stated
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Sakhel 2007 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias High risk Comment: the included women in the u-
hCG group had a greater mean duration of
infertility than the r-hCG group
Schmidt-Sarosi 1995
Methods Single centre, parallel design. Random number table, concealment of allocation not
stated
Blinding not stated. Follow up until birth characteristics were available
Power calculation performed: when assuming a 20% pregnancy rate and defining a
clinically important pregnancy rate of at least 10%, 6600 cycles were needed in each
treatment group to achieve a power of 80%
No ITT
Participants 26 women, 26 cycles
Inclusion criteria: at least unilateral tubal patency, laboratory values euthyroid and nor-
moprolactinemic and > 5 million motile sperm cells after swim up
Exclusion criteria: previously undergone clomiphene citrate/hCG stimulation
Mean age of women: hCG group: 30.2 yrs and GnRH-a group: 34.5 yrs
Duration of subfertility: not stated
Type of subfertility: anovulation, luteal phase defect or unexplained
Interventions Stimulation method: 50 mg clomiphene citrate from cycle day 5 to 9
Intervention: two doses of 400 µg nafarelin intranasal (IN) versus 5000 IU hCG IM
injection. IUI 48h after the first dose of nafarelin or 36 h after hCG injection Luteal
support was given with nafarelin or hCG in each group
Type of semen injected: not stated
Insemination procedure: not stated, single insemination
Outcomes Live birth rate per couple: GnRH-a group: 2/11 (18.2%). hCG group: 2/15 (13.3%)
Pregnancy rate per couple: GnRH-a group: 3/11 (27.3%). hCG group: 2/15 (13.3%)
Miscarriage rate: GnRH-a group: 1/3 (33.3%). hCG group: 0/2 (0%)
No multiple pregnancies and no OHSS
Costs: not stated
Pregnancy diagnosed: no definition of pregnancy was stated
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Schmidt-Sarosi 1995 (Continued)
Notes Concealment of allocation not stated
Small groups using different forms of luteal support
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised via a random
numbers table
Allocation concealment (selection bias) Unclear risk None stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data addressed adequately
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias High risk Comment: the use of different forms of
luteal support in both groups
Scott 1994
Methods Single centre, cross-over. Randomisation through random number table. Concealment
of allocation: sealed envelopes
Blinding was used: the sonographer was blinded to which treatment the woman had
received
Study duration and follow up not stated. Power calculation: only stated for the incidence
of unruptured follicle syndrome. ITT not stated
Participants 30 women, 30 first cycles
Inclusion criteria: women with subfertility of at least one year and ovulatory cycles
Exclusion criteria: not stated
Mean age of women: 32.2 ± 1.0 SD
Duration of subfertility: at least one year, not further stated
Type of subfertility: unexplained (n = 26), male factor ( n = 4)
Interventions Stimulation method: clomiphene citrate 100 mg orally each day, from cycle day 5 to 9
Intervention: 2 mg of leuprolide acetate or 10.000 IU hCG. IUI after 40 hours
Type of semen: not stated. Insemination procedure: not stated. One insemination
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Scott 1994 (Continued)
Outcomes Pregnancy rate per couple: 20% GnRH-a group, 6.7% hCG group
Live birth rate per couple: 20% GnRH-a group, 6.7% hCG group
Secondary outcome measures: not stated
Costs: not stated
Pregnancy diagnosed: not stated
Notes Primary outcome measure was not pregnancy rate, but the endocrine dynamics during
the periovular interval, the incidence of luteinised unruptured follicle syndrome and the
characteristics of the adequate luteal phase
Setting: Division of Reproductive Endocrinology, Department of Obstetrics and Gyne-
cology, Wilford Hall Medical Center, Lackland Air Force Base, Texas
No funding stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk None stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The sonologists were blinded to which
treatment the couples had received to min-
imize the risk of observer bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Incomplete data adequately addressed
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias Low risk No other bias
Shalev 1995
Methods Trial design: parallel. Randomisation by self made computer program. Concealment of
allocation by third party
Blinding was used. Follow up: until birth characteristics were available. Power calculation
for reduction in rate of OHSS was performed, but not further mentioned. ITT was not
performed
Study duration not stated
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Shalev 1995 (Continued)
Participants 48 women, 140 cycles
Inclusion criteria: anovulation, oligo-ovulation or unexplained infertility
Exclusion criteria: women at high risk of developing severe OHSS (> 20 mature pre-
ovulatory follicles and estradiol concentrations > 4000 pg/ml)
Mean age of women: hCG group: 30.4 yrs and GnRH-a group: 29.2 yrs
Duration of subfertility: not stated per group, but at least one year
Type of subfertility: anovulation, oligo-ovulation or unexplained infertility
Interventions Stimulation method: individualized regime of HMG starting on cycle day five
Intervention: 0.1 mg triptorelin or 10.000 IU hCG, IUI 24 and 48 hours after injection
Type of semen injected: husband. Semen prepared by discontinuous Percoll gradient and
washed twice. A volume of 0.3 to 0.5 ml of sperm suspension containing an average of
19 x 106 per ml of motile spermatozoa
Insemination procedure: Tefcat catheter high in uterine cavity
Number of inseminations: two
Outcomes Outcome live birth rate per cycle: 17.6% hCG group, 12.5% GnRH-a group
Pregnancy rate per cycle: 26.5% hCG group, 15.3% GnRH-a group
Pregnancy rate per couple: 45.8% hCG group, 66.7% GnRH-a group
Multiple pregnancy rate: 0% hCG group, 18% GnRH-a group
Miscarriage rate: 33.3% hCG group, 18% GnRH-a group
OHSS rate: 11.8% hCG group, 5.6% GnRH-a group
Ectopic pregnancy rate: not stated
Costs: not stated
Pregnancy diagnosed: rising concentration of hCG. Clinical pregnancy was diagnosed
by fetal heart beat
Notes Very high pregnancy rate per couple




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Author comment: randomisation was per-
formed using a self made computer pro-
gram. Adequate sequence generation not
stated
Allocation concealment (selection bias) Low risk Author comment: third party
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding stated, but outcome not likely
to be influenced either way
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Shalev 1995 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding stated, but outcome not likely
to be influenced either way
Incomplete outcome data (attrition bias)
All outcomes
Low risk Incomplete data adequately addressed
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias Low risk No other bias
Sharma 2011
Methods Single centre, prospective randomised study. Concealment of allocation with sealed en-
velopes
No blinding was stated. Follow up until clinical pregnancy. No power calculation was
stated. No ITT analysis was stated
Study duration: January to October 2010
Participants 505 women were eligible, 450 women included
Inclusion criteria: unexplained subfertility with two previous failed clomiphene citrate/
IUI cycles, with follicular endometrial dys-synchrony (follicle ≥ 18 mm, endometrial
thickness < 7 mm)
Exclusion criteria: women with persistent endometrial thickness < 7 mm. IUI was can-
celled when a luteinised unruptured follicle was present or semen collection failed
Mean age of women: not state
Mean duration of subfertility: not stated
Type of subfertility: unexplained infertility
Interventions Stimulation method: clomiphene citrate 100 mg
Intervention: 1 mg GnRH-a versus 5000 IU uhCG im injection
IUI after confirmation of ovulation (time frame not stated)
Type of semen injected:not stated
Insemination procedure: not stated, one insemination. Luteal support was given: 300
mg progesterone vaginally
Outcomes Ongoing pregnancy rate per couple: 9.8% (GnRH-a) versus 4.4% (hCG)
Clinical pregnancy rate per couple: 10.2% (GnRH-a) versus 4.9% (hCG)
Miscarriage rate: 10% (GnRH-a) versus 8.7% (hCG)
Clinical pregnancy defined as the presence of gestational sac with cardiac activity on
ultrasound
Notes Unclear why 20 couples were excluded who met the criteria for ovulation triggering
Setting: Institute of reproductive medicine, Kolkata, India
Results could not be included in the meta-analysis since it was not clear whether the
results were given for the total group of included couples or only those couples who
underwent an IUI procedure
Funding: not stated
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Sharma 2011 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Only states ‘sealed envelopes’, not opaque
or numbered
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
Incomplete outcome data (attrition bias)
All outcomes
High risk Unclear why 20 couples were excluded be-
fore randomisation
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias Low risk No other bias
Weiss 2010
Methods Single centre, parallel. Random number generator, sealed opaque envelopes
No blinding used. Follow up until after delivery. No power calculation performed: the
study was stopped before reaching significant power following an unusual number of
multi-fetal pregnancies. No ITT analysis: couples were withdrawn from the study if they
were transferred to IVF or IUI was cancelled
Study duration: from July 2008 to not stated
Participants 92 completed cycles
Inclusion criteria: ovulatory disorders,male factor, partialmechanical factor, endometrio-
sis, unexplained infertility
Exclusion criteria: known allergy to the utilized drugs, No patent tubes, sperm count
< 1 million total motile sperm of normal morphology, women who are candidates for
mono-ovulation, failure to receive consent and women with baseline functional cysts (>
12 mm)
Mean age of women: 31.6 ± 5.8 yrs (36 h after hCG) versus 31.8 ± 6.5 yrs (42 h after
hCG) versus 29.4 ± 5.7 yrs (48 h after hCG)
Mean duration of subfertility: 2.2 ± 1.5 yrs (36 h after hCG) versus 2.1 ± 1.4 yrs (42 h
after hCG versus 2.1 ± 1.3 yrs (48 h after hCG)
Type of subfertility: mild tomoderate male infertility, anovulation, unilateral mechanical
factor, endometriosis and unexplained infertility
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Weiss 2010 (Continued)
Interventions Stimulation method: gonadotropins either recombinant or urinary. Dosing was flexible
and based on womens’ age
Interventions: IUI either 36 hours, 42 hours or 48 hours after hCG (dosage not stated)
Type of semen injected: husband or donor
Insemination procedure: not stated, one insemination
Outcomes Live birth rate per cycle: 5/35 (14%) 36 h after hCG, 9/24 (38%) 42 h after hCG, 7/33
(21%) 48 h after hCG
Pregnancy rate per cycle: 10/35 (29%) 36 h after hCG, 9/24 (38%) 42 h after hCG, 8/
33 (24%) 48 h after hCG
Number of miscarriage: 5/10 (50%) 36 h after hCG, 0/9 (0%) 42 h after hCG, 1/8
(11%) 48 h after hCG
Multiple pregnancy rate: 3/10 (30%) 36 h after hCG, 4/9 (44%) 42 h after hCG, 3/8
(38%) 48 h after hCG
Tubal pregnancy rate: 0/35 (0%) 36 h after hCG, 0/24 (0%) 42 h after hCG, 1/33 (3%)
48 h after hCG
Pregnancy diagnosed: transvaginal ultrasound demonstrating a gestational sac
Notes Inclusion of women with ovulatory disorders
Number of women included not stated
Study stopped prematurely because of an unusual number of multi-fetal pregnancies
Setting: HaEmek Medical Center. Afula, Israel
Funding: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Low risk Author comment: The numbers were
placed in consecutively ordered sealed
opaque envelopes. At the time of enrol-
ment, the envelope was opened and group
assignment was made
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data adequately addressed (9
women were withdrawn for hyperstimula-
tion, premature ovulation or for lack of re-
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Weiss 2010 (Continued)
sponse to gonadotropins)
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias High risk Comment: there were significantly more
miscarriages in the 36 h group
Zreik 1999
Methods Single centre, cross-over. Randomisation was performed with the use of a computer
generated random number table
Blinding until informed consent was obtained. Follow up not clearly stated. ITT was
performed
Duration: from September 1994 to July 1996
Participants 54 women, 53 first cycles
Inclusion criteria: normal hysterosalpingography, a normal endometrium biopsy, history
of clomiphene citrate use of < six months’ duration
Exclusion criteria: not stated
Mean age of women: hCG group: 32 range 24 to 41 LH surge group: 33 range 25 to 41
years
Duration of subfertility: 2.8 years, range 1 to 8 hCG group, 3.2 years, range 1 to 10 LH
group
Type of subfertility: unexplained, male factor, anovulation
Interventions 50-100 clomiphene citrate from cycle day three to seven
LH group: home monitoring u-LH, IUI daily after positive test for the next two days.
hCG group: 10,000 IU hCG, IUI daily for the next two days
type of semen injected not stated
Insemination procedure: not stated, double insemination
Outcomes Outcome pregnancy rate per couple: 4% LH group, 7.1% hCG group
Secondary outcome measures: not stated
Costs: not stated
Pregnancy diagnosed: no definition of pregnancy was stated
Notes Cross-over study design. Only the first cycle pre-cross over data were used. Inclusion of
15 women with anovulation. Pregnancy rate very low
Setting: Yale Reproductive Medicine Center, New Haven, Conneticut, USA
No funding stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The use of a computer generated random
number table
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Zreik 1999 (Continued)
Allocation concealment (selection bias) Unclear risk States that the assignment was not known
to the treating physician or the couple until
consent was obtained, but does not state
method of concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding, but outcome not likely to be
influenced
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data adequately addressed
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias Low risk No other bias
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Agarwal 1995 Retrospective study
Arici 1994 Compared stimulated with non-stimulated cycles. Double and single insemination used
Baroni 2001 Compared different timing methods at different follicle sizes at different times to IUI
Barratt 1989 Endo-cervical and peri-cervical insemination
Casadei 2006 Comparing single IUI versus double IUI versus TI with IUI
Cedrin-Durnerin 1993 Quasi-randomised trial
Check 1994 Prospective non-randomised study
Claman 2000 Abstract of an included study
Claman 2004a Abstract of an included study
Claraz 1989 Intracervical insemination
Costa Franco 2006 Retrospective study design
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Diaz 2003a Inadequate randomisation; random numbers in an open list
Diaz 2003b Abstract of an excluded study
Diaz 2008 Inadequate randomisation; random numbers in an open list. Same study as Diaz 2003a
Egbase 2003 Inclusion of PCOS women only
Federman 1990 Comparing single versus double insemination. Cross-over study
Fischer 1993 Investigates the time interval from hCG administration to follicular wall rupture
Fondop 2005 Cohort study
George 2007 Timed intercourse
Gerris 1995 Prospective non-randomised study
Gerrits 2011 Trial to determine the safety of orally administered LH agonists
Ghanem 2011 Cohort study
Ghazizadeh 2009 Comparing the usefulness of GnRH antagonist administration in preventing premature LH surge
Ghosh Dastidar 2009 Comparing the supplementation of LH in the stimulation protocol
Int rhCG study group 2001 Included anovulatory patients only. Used both IUI and timed intercourse
Khattab 2005 Retrospective study design
Kossoy 1989 Cohort study
Kotecki 2005 Comparison of five different ovarian stimulation protocols
Lewis 2002 Abstract of an included study
Lewis 2003 Abstract of an included study
Martinez 1994 Retrospective study
Meherji 2004 Commentary report
Nulsen 1993 Cross-over study. Comparing stimulated with non-stimulated cycles. Comparing double versus single
insemination
Odem 1991 Quasi-randomised trial. Insemination through cervical cap
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Panchal 2009 Cohort study
Papageorgiou 1995 Comparing stimulated with non-stimulated cycles
Pierson 2002 Dose finding study
Pirard 2005 Investigated the luteal support between hCG triggered cycles and GnRHa administered cycles
Propst 2007 Cohort study. Not the comparison of interest
Propst 2012 Not comparison of interest
Ragni 1999 Compared a single peri-ovulatory IUI with two double IUI regimes
Ramon 2009 Ultrasound guided IUI versus blind IUI
Ramon 2009a Abstract of an excluded study
Robinson 1992 Inclusion of donor insemination only
Romeu 1997a Prospective non-randomised trial
Romeu 1997b Failure to use a truly randomised design
Sakhel 2004 Abstract of an included study
Scarpellini 1991 Also comparing IUI with timed intercourse
Shanis 1995 Not truly randomised
Silverberg 1991 Comparing single versus double insemination
Tavaniotou 2003 Cohort study
Tonguc 2010 Inadequate randomisation; sequentially enrolled into three groups according to their entry
Wang 2001 Abstract of an excluded study
Wang 2006 Ovulation induction at different follicle sizes
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Characteristics of studies awaiting assessment [ordered by study ID]
Aydin 2013
Methods Single centre, parallel. Randomisation was performed with the use of a computer generated random numbers, upon
enrolment an opaque envelope was opened
Follow up until clinical pregnancy. ITT was performed
Duration: from September 2011 to January 2013
Participants 220 women, 220 first cycles
Inclusion criteria: normal hysterosalpingography, normal hormone essay, semen analysis total progressive motile
sperm count > 5 million/ml with > 4% morphology after sperm preparation
Exclusion criteria: women with endocrinologic disorders, women with any history of surgery on the reproductive
system, women < 20 years and > 35 years, women with expected to be poor responders due to day 3 baseline
ultrasonography and or FSH > 10 mIU/ml, estradiol > 40 pg/ml and an antral follicle count (AFC < 6), women who
had previously smoked, with advanced male factor infertility (referred for IVF)
Mean age of women: 34 to 36 hrs after hCG group: 30.6 ± 3.4 IUI with hCG: 30.7 ± 3.3
Duration of subfertility: 4.9 ± 4.9 years 34 to 36 hrs after hCG group, 5.2 ± 4.7 years, IUI with hCG group
Type of subfertility: unexplained, male factor
Interventions 75 to 112.5 IU r-FSH from cycle day 3, with low dose step up. Ovulation triggering 250 µg r-hCG
Type of semen: partner
Insemination procedure: two-layer density gradient separation technique, single IUI
Outcomes Outcome pregnancy rate per couple: 10/106 (9.4%) 34 to 36 hrs after hCG, 12/98 (12.2%) IUI with hCG group
Secondary outcome measures: not stated
Costs: not stated
Pregnancy diagnosed: presence of an embryo with cardiac activity on ultrasound
Notes Setting: Eskisehir Osmangazi University, Center for Reproductive Health, Eskisehir, Turkey
Long duration of subfertility
No funding stated
Blockeel 2014
Methods Single centre, parallel designed randomised trial with computer generated list. Concealment of allocation: third party
Single blinding used (investigator). Follow up until 12 weeks pregnancy
Participants Women who are candidates for intrauterine insemination in a natural cycle
Inclusion criteria: Age between 18 and 39 yrs. Donor semen. Cycle with less then 3 follicles reaching 15 mm or
more, basal hormonal values of progesterone Exclusion criteria: after more than 6 intrauterine inseminations, tubal
infertility
Interventions IUI 24 or 48 hours after spontaneous LH peak
Outcomes Primary outcome measure: Clinical pregnancy rate per couple. Secondary outcome measure: live birth rate
Notes Inclusion of donor semen
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Dehghani 2014
Methods Single centre, parallel designed randomised trial with computer generated list. Concealment of allocation: third party
Single blinding used (investigator). Follow up until 12 weeks pregnancy
Participants 100 infertile couples were divided into two groups
Inclusion criteria: 18 to 35 years; open fallopian tubes confirmed by hysterosalpingography
Exclusion criteria: tubal factor, severe endometriosis, hypothalamic amenorrhea, or severe oligospermia (sperm count
lower than 5 million per ml based on WHO 2012 classification) (Table 1) in their husbands
Interventions HCG injection before IUI and HCG injection after IUI
Outcomes The main outcome measure was the result of an hCG test that was done two weeks after the IUI; if it was positive,
transvaginal sonography would be performed in the seventh week for clinical confirmation of pregnancy
Notes
Mostafa 2014
Methods Single centre, parallel designed randomised trial with random computer generated table. Concealment of allocation:
not stated
Blinding: not stated. Follow up: till pregnancy test
Participants One hundred infertile couples with a diagnosis of unexplained infertility who had been scheduled for intrauterine
insemination (IUI) by husband semen
Inclusion criteria: age of female partner less than 37 years; a normal basal hormonal profile (FSH, LH, TSH, E2 and
prolactin); a satisfactory basal (day 2) transvaginal ultrasound examination
Cases with failed previous 3 IUI trials were excluded
Interventions Study group: 50 women in whom hCG (10,000 IU) was injected 3 to 5 min after IUI
Control group: 50 women in whom hCG (10,000 IU) was injected 24 to 32 h before IUI
Outcomes Pregnancy rate
Notes All patients gave informed consent and the study was approved by local ethics committee for scientific research
Characteristics of ongoing studies [ordered by study ID]
OVO R&D 2012
Trial name or title Combining Urinary Luteinizing hormone Testing with ultrasound monitoring in intrauterine insemination
cycles
Methods Parallel designed randomised trial
Participants Women who undergo IUI treatment for unexplained infertility, mild male factor or donor insemination
Inclusion criteria: women between 18 and 39 years. natural and stimulated cycles with clomiphene citrate or
letrozole. At least one patent tube and an antral follicular count ≥ 10 and FSH ≤ 10
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OVO R&D 2012 (Continued)
Interventions Ultrasound monitoring with hCG administration at a leading follicle of 18 mm versus ultrasound monitoring
with LH testing in urine
Outcomes Primary outcome measure: pregnancy rate. Secondary outcome measure: rate of positive LH testing
Starting date January 2011
Contact information Harnois M, Levesque C, Ovo fertilite, Montreal, Canada
Notes Inclusion of donor semen. Sponsored study
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D A T A A N D A N A L Y S E S
Comparison 1. hCG versus LH surge




participants Statistical method Effect size
1 live birth rate per couple 1 24 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.06, 18.08]
2 pregnancy rate per couple 4 275 Odds Ratio (M-H, Fixed, 95% CI) 1.33 [0.72, 2.45]
3 multiple pregnancy rate per
pregnancy
2 42 Odds Ratio (M-H, Fixed, 95% CI) 1.13 [0.17, 7.60]
Comparison 2. u-hCG versus r-hCG




participants Statistical method Effect size
1 live birth rate per couple 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2 pregnancy rate per couple 2 409 Odds Ratio (M-H, Fixed, 95% CI) 1.02 [0.65, 1.57]
3 multiple pregnancy rate per
pregnancy
2 109 Odds Ratio (M-H, Fixed, 95% CI) 0.99 [0.40, 2.47]
4 miscarriage rate per pregnancy 2 109 Odds Ratio (M-H, Fixed, 95% CI) 0.57 [0.13, 2.47]
5 OHSS rate per cycle 2 468 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. Short versus long interval




participants Statistical method Effect size
1 live birth rate per couple 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 24 hours versus 34-36
hours
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 pregnancy rate per couple 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 24 hours versus 34-36
hours
2 234 Odds Ratio (M-H, Fixed, 95% CI) 0.55 [0.31, 0.98]
2.2 24 hours versus 48 hours 1 30 Odds Ratio (M-H, Fixed, 95% CI) 0.44 [0.10, 1.92]
2.3 34-36 hours versus 48
hours
1 30 Odds Ratio (M-H, Fixed, 95% CI) 0.58 [0.14, 2.48]
3 miscarriage rate per pregnancy 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 24 hours versus 34-36
hours
2 67 Odds Ratio (M-H, Fixed, 95% CI) 1.58 [0.35, 7.16]
3.2 24 hours versus 48 hours 1 15 Odds Ratio (M-H, Fixed, 95% CI) 4.0 [0.27, 58.56]
3.3 34-36 hours versus 48
hours
1 16 Odds Ratio (M-H, Fixed, 95% CI) 1.33 [0.07, 25.91]
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Comparison 4. hCG versus GnRH-a




participants Statistical method Effect size
1 live birth rate per couple 3 104 Odds Ratio (M-H, Fixed, 95% CI) 1.04 [0.42, 2.56]
2 pregnancy rate per couple 4 206 Odds Ratio (M-H, Fixed, 95% CI) 1.14 [0.63, 2.08]
3 multiple pregnancy rate per
pregnancy
4 74 Odds Ratio (M-H, Fixed, 95% CI) 0.15 [0.02, 1.38]
4 miscarriage rate per pregnancy 4 74 Odds Ratio (M-H, Fixed, 95% CI) 1.72 [0.48, 6.20]
5 OHSS per cycle 3 456 Odds Ratio (M-H, Fixed, 95% CI) 2.27 [0.65, 7.91]
Comparison 5. Early hCG versus late hCG




participants Statistical method Effect size
1 pregnancy rate per couple 1 612 Odds Ratio (M-H, Fixed, 95% CI) 1.32 [0.77, 2.25]
2 miscarriage rate 1 65 Odds Ratio (M-H, Fixed, 95% CI) 0.51 [0.08, 3.28]
Comparison 6. Different dosages of hCG




participants Statistical method Effect size
1 pregnancy rate per couple 1 66 Odds Ratio (M-H, Fixed, 95% CI) 1.38 [0.28, 6.71]
Analysis 1.1. Comparison 1 hCG versus LH surge, Outcome 1 live birth rate per couple.
Review: Synchronised approach for intrauterine insemination in subfertile couples
Comparison: 1 hCG versus LH surge
Outcome: 1 live birth rate per couple
Study or subgroup hCG LH surge Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martinez 1991a 1/12 1/12 100.0 % 1.00 [ 0.06, 18.08 ]
Total (95% CI) 12 12 100.0 % 1.00 [ 0.06, 18.08 ]
Total events: 1 (hCG), 1 (LH surge)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours hCG Favours LH surge
69Synchronised approach for intrauterine insemination in subfertile couples (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.2. Comparison 1 hCG versus LH surge, Outcome 2 pregnancy rate per couple.
Review: Synchronised approach for intrauterine insemination in subfertile couples
Comparison: 1 hCG versus LH surge
Outcome: 2 pregnancy rate per couple
Study or subgroup hCG LH surge Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martinez 1991a 1/12 1/12 5.1 % 1.00 [ 0.06, 18.08 ]
Zreik 1999 2/28 1/25 5.5 % 1.85 [ 0.16, 21.69 ]
Martinez 1991b 4/24 5/24 23.3 % 0.76 [ 0.18, 3.26 ]
Lewis 2006 23/75 17/75 66.0 % 1.51 [ 0.73, 3.13 ]
Total (95% CI) 139 136 100.0 % 1.33 [ 0.72, 2.45 ]
Total events: 30 (hCG), 24 (LH surge)
Heterogeneity: Chi2 = 0.79, df = 3 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours LH surge Favours hCG
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Analysis 1.3. Comparison 1 hCG versus LH surge, Outcome 3 multiple pregnancy rate per pregnancy.
Review: Synchronised approach for intrauterine insemination in subfertile couples
Comparison: 1 hCG versus LH surge
Outcome: 3 multiple pregnancy rate per pregnancy
Study or subgroup hCG LH surge Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lewis 2006 3/23 2/17 100.0 % 1.13 [ 0.17, 7.60 ]
Martinez 1991a 0/1 0/1 Not estimable
Total (95% CI) 24 18 100.0 % 1.13 [ 0.17, 7.60 ]
Total events: 3 (hCG), 2 (LH surge)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours hCG Favours LH surge
Analysis 2.1. Comparison 2 u-hCG versus r-hCG, Outcome 1 live birth rate per couple.
Review: Synchronised approach for intrauterine insemination in subfertile couples
Comparison: 2 u-hCG versus r-hCG
Outcome: 1 live birth rate per couple
Study or subgroup u-hCG r-hCG Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sakhel 2007 36/144 31/140 1.17 [ 0.68, 2.03 ]
0.01 0.1 1 10 100
Favours rhCG Favours uhCG
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Analysis 2.2. Comparison 2 u-hCG versus r-hCG, Outcome 2 pregnancy rate per couple.
Review: Synchronised approach for intrauterine insemination in subfertile couples
Comparison: 2 u-hCG versus r-hCG
Outcome: 2 pregnancy rate per couple
Study or subgroup u-hCG r-hCG Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lorusso 2008 14/61 16/64 30.4 % 0.89 [ 0.39, 2.03 ]
Sakhel 2007 41/144 38/140 69.6 % 1.07 [ 0.64, 1.80 ]
Total (95% CI) 205 204 100.0 % 1.02 [ 0.65, 1.57 ]
Total events: 55 (u-hCG), 54 (r-hCG)
Heterogeneity: Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.95)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours r-hCG Favours u-hCG
Analysis 2.3. Comparison 2 u-hCG versus r-hCG, Outcome 3 multiple pregnancy rate per pregnancy.
Review: Synchronised approach for intrauterine insemination in subfertile couples
Comparison: 2 u-hCG versus r-hCG
Outcome: 3 multiple pregnancy rate per pregnancy
Study or subgroup u-hCG r-hCG Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lorusso 2008 0/14 0/16 Not estimable
Sakhel 2007 15/41 14/38 100.0 % 0.99 [ 0.40, 2.47 ]
Total (95% CI) 55 54 100.0 % 0.99 [ 0.40, 2.47 ]
Total events: 15 (u-hCG), 14 (r-hCG)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours u-hCG Favours r-hCG
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Analysis 2.4. Comparison 2 u-hCG versus r-hCG, Outcome 4 miscarriage rate per pregnancy.
Review: Synchronised approach for intrauterine insemination in subfertile couples
Comparison: 2 u-hCG versus r-hCG
Outcome: 4 miscarriage rate per pregnancy
Study or subgroup u-hCG r-hCG Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lorusso 2008 1/14 1/16 18.0 % 1.15 [ 0.07, 20.34 ]
Sakhel 2007 2/41 4/38 82.0 % 0.44 [ 0.08, 2.53 ]
Total (95% CI) 55 54 100.0 % 0.57 [ 0.13, 2.47 ]
Total events: 3 (u-hCG), 5 (r-hCG)
Heterogeneity: Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours u-hCG Favours r-hCG
Analysis 2.5. Comparison 2 u-hCG versus r-hCG, Outcome 5 OHSS rate per cycle.
Review: Synchronised approach for intrauterine insemination in subfertile couples
Comparison: 2 u-hCG versus r-hCG
Outcome: 5 OHSS rate per cycle
Study or subgroup u-hCG r-hCG Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lorusso 2008 0/88 0/96 Not estimable
Sakhel 2007 0/144 0/140 Not estimable
Total (95% CI) 232 236 Not estimable
Total events: 0 (u-hCG), 0 (r-hCG)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours u-hCG Favours r-hCG
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Analysis 3.1. Comparison 3 Short versus long interval, Outcome 1 live birth rate per couple.
Review: Synchronised approach for intrauterine insemination in subfertile couples
Comparison: 3 Short versus long interval
Outcome: 1 live birth rate per couple
Study or subgroup short (24 h) long (36 h) Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 24 hours versus 34-36 hours
Rahman 2011 18/100 31/104 0.52 [ 0.27, 1.00 ]
0.01 0.1 1 10 100
Favours long interval Favours short interval
Analysis 3.2. Comparison 3 Short versus long interval, Outcome 2 pregnancy rate per couple.
Review: Synchronised approach for intrauterine insemination in subfertile couples
Comparison: 3 Short versus long interval
Outcome: 2 pregnancy rate per couple
Study or subgroup short (24 h) long (36 h) Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 24 hours versus 34-36 hours
AboulGheit 2010 6/15 7/15 13.6 % 0.76 [ 0.18, 3.24 ]
Rahman 2011 20/100 34/104 86.4 % 0.51 [ 0.27, 0.97 ]
Subtotal (95% CI) 115 119 100.0 % 0.55 [ 0.31, 0.98 ]
Total events: 26 (short (24 h)), 41 (long (36 h))
Heterogeneity: Chi2 = 0.24, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.02 (P = 0.043)
2 24 hours versus 48 hours
AboulGheit 2010 6/15 9/15 100.0 % 0.44 [ 0.10, 1.92 ]
Subtotal (95% CI) 15 15 100.0 % 0.44 [ 0.10, 1.92 ]
Total events: 6 (short (24 h)), 9 (long (36 h))
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
0.002 0.1 1 10 500
Favours long interval Favours short interval
(Continued . . . )
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(. . . Continued)
Study or subgroup short (24 h) long (36 h) Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
3 34-36 hours versus 48 hours
AboulGheit 2010 7/15 9/15 100.0 % 0.58 [ 0.14, 2.48 ]
Subtotal (95% CI) 15 15 100.0 % 0.58 [ 0.14, 2.48 ]
Total events: 7 (short (24 h)), 9 (long (36 h))
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
Test for subgroup differences: Chi2 = 0.08, df = 2 (P = 0.96), I2 =0.0%
0.002 0.1 1 10 500
Favours long interval Favours short interval
Analysis 3.3. Comparison 3 Short versus long interval, Outcome 3 miscarriage rate per pregnancy.
Review: Synchronised approach for intrauterine insemination in subfertile couples
Comparison: 3 Short versus long interval
Outcome: 3 miscarriage rate per pregnancy
Study or subgroup short (24 h) long (34-36 h) Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 24 hours versus 34-36 hours
AboulGheit 2010 2/6 1/7 23.5 % 3.00 [ 0.20, 45.24 ]
Rahman 2011 2/20 3/34 76.5 % 1.15 [ 0.18, 7.53 ]
Subtotal (95% CI) 26 41 100.0 % 1.58 [ 0.35, 7.16 ]
Total events: 4 (short (24 h)), 4 (long (34-36 h))
Heterogeneity: Chi2 = 0.33, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
2 24 hours versus 48 hours
AboulGheit 2010 2/6 1/9 100.0 % 4.00 [ 0.27, 58.56 ]
Subtotal (95% CI) 6 9 100.0 % 4.00 [ 0.27, 58.56 ]
Total events: 2 (short (24 h)), 1 (long (34-36 h))
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
3 34-36 hours versus 48 hours
0.001 0.01 0.1 1 10 100 1000
Favours long interval Favours short interval
(Continued . . . )
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(. . . Continued)
Study or subgroup short (24 h) long (34-36 h) Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AboulGheit 2010 1/7 1/9 100.0 % 1.33 [ 0.07, 25.91 ]
Subtotal (95% CI) 7 9 100.0 % 1.33 [ 0.07, 25.91 ]
Total events: 1 (short (24 h)), 1 (long (34-36 h))
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Chi2 = 0.40, df = 2 (P = 0.82), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours long interval Favours short interval
Analysis 4.1. Comparison 4 hCG versus GnRH-a, Outcome 1 live birth rate per couple.
Review: Synchronised approach for intrauterine insemination in subfertile couples
Comparison: 4 hCG versus GnRH-a
Outcome: 1 live birth rate per couple
Study or subgroup hCG GnRH-a Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schmidt-Sarosi 1995 2/15 2/11 21.5 % 0.69 [ 0.08, 5.86 ]
Scott 1994 1/15 3/15 30.1 % 0.29 [ 0.03, 3.12 ]
Shalev 1995 12/24 9/24 48.4 % 1.67 [ 0.53, 5.27 ]
Total (95% CI) 54 50 100.0 % 1.04 [ 0.42, 2.56 ]
Total events: 15 (hCG), 14 (GnRH-a)
Heterogeneity: Chi2 = 1.91, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours GnRH-a Favours hCG
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Analysis 4.2. Comparison 4 hCG versus GnRH-a, Outcome 2 pregnancy rate per couple.
Review: Synchronised approach for intrauterine insemination in subfertile couples
Comparison: 4 hCG versus GnRH-a
Outcome: 2 pregnancy rate per couple
Study or subgroup hCG GnRH-a Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Andr s-Oros 2008 21/60 15/42 57.3 % 0.97 [ 0.42, 2.21 ]
Schmidt-Sarosi 1995 2/15 3/11 15.0 % 0.41 [ 0.06, 3.01 ]
Scott 1994 1/15 3/15 14.0 % 0.29 [ 0.03, 3.12 ]
Shalev 1995 18/24 11/24 13.7 % 3.55 [ 1.04, 12.06 ]
Total (95% CI) 114 92 100.0 % 1.14 [ 0.63, 2.08 ]
Total events: 42 (hCG), 32 (GnRH-a)
Heterogeneity: Chi2 = 5.74, df = 3 (P = 0.12); I2 =48%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours GnRHa Favours hCG
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Analysis 4.3. Comparison 4 hCG versus GnRH-a, Outcome 3 multiple pregnancy rate per pregnancy.
Review: Synchronised approach for intrauterine insemination in subfertile couples
Comparison: 4 hCG versus GnRH-a
Outcome: 3 multiple pregnancy rate per pregnancy
Study or subgroup hCG GnRH-a Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Andr s-Oros 2008 0/21 1/15 36.3 % 0.22 [ 0.01, 5.91 ]
Schmidt-Sarosi 1995 0/2 0/3 Not estimable
Scott 1994 0/1 0/3 Not estimable
Shalev 1995 0/18 2/11 63.7 % 0.10 [ 0.00, 2.36 ]
Total (95% CI) 42 32 100.0 % 0.15 [ 0.02, 1.38 ]
Total events: 0 (hCG), 3 (GnRH-a)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.68 (P = 0.094)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours hCG Favours GnRH-a
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Analysis 4.4. Comparison 4 hCG versus GnRH-a, Outcome 4 miscarriage rate per pregnancy.
Review: Synchronised approach for intrauterine insemination in subfertile couples
Comparison: 4 hCG versus GnRH-a
Outcome: 4 miscarriage rate per pregnancy
Study or subgroup hCG GnRH-a Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Andr s-Oros 2008 3/21 1/15 26.8 % 2.33 [ 0.22, 24.92 ]
Schmidt-Sarosi 1995 0/2 1/3 28.8 % 0.33 [ 0.01, 12.82 ]
Scott 1994 0/1 0/3 Not estimable
Shalev 1995 6/18 2/11 44.4 % 2.25 [ 0.37, 13.87 ]
Total (95% CI) 42 32 100.0 % 1.72 [ 0.48, 6.20 ]
Total events: 9 (hCG), 4 (GnRH-a)
Heterogeneity: Chi2 = 0.92, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours hCG Favours GnRH-a
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Analysis 4.5. Comparison 4 hCG versus GnRH-a, Outcome 5 OHSS per cycle.
Review: Synchronised approach for intrauterine insemination in subfertile couples
Comparison: 4 hCG versus GnRH-a
Outcome: 5 OHSS per cycle
Study or subgroup hCG GnRH-a Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Andr s-Oros 2008 0/158 0/132 Not estimable
Schmidt-Sarosi 1995 0/15 0/11 Not estimable
Shalev 1995 8/68 4/72 100.0 % 2.27 [ 0.65, 7.91 ]
Total (95% CI) 241 215 100.0 % 2.27 [ 0.65, 7.91 ]
Total events: 8 (hCG), 4 (GnRH-a)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours hCG Favours GnRH-a
Analysis 5.1. Comparison 5 Early hCG versus late hCG, Outcome 1 pregnancy rate per couple.
Review: Synchronised approach for intrauterine insemination in subfertile couples
Comparison: 5 Early hCG versus late hCG
Outcome: 1 pregnancy rate per couple
Study or subgroup early hCG late hCG Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
da Silva 2012 34/309 26/303 100.0 % 1.32 [ 0.77, 2.25 ]
Total (95% CI) 309 303 100.0 % 1.32 [ 0.77, 2.25 ]
Total events: 34 (early hCG), 26 (late hCG)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours late hCG Favours early hCG
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Analysis 5.2. Comparison 5 Early hCG versus late hCG, Outcome 2 miscarriage rate.
Review: Synchronised approach for intrauterine insemination in subfertile couples
Comparison: 5 Early hCG versus late hCG
Outcome: 2 miscarriage rate
Study or subgroup early hCG late hCG Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
da Silva 2012 2/36 3/29 100.0 % 0.51 [ 0.08, 3.28 ]
Total (95% CI) 36 29 100.0 % 0.51 [ 0.08, 3.28 ]
Total events: 2 (early hCG), 3 (late hCG)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours early hCG Favours late hCG
Analysis 6.1. Comparison 6 Different dosages of hCG, Outcome 1 pregnancy rate per couple.
Review: Synchronised approach for intrauterine insemination in subfertile couples
Comparison: 6 Different dosages of hCG
Outcome: 1 pregnancy rate per couple
Study or subgroup 500 ug hCG 250 ug hCG Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nikbakht 2012 4/33 3/33 100.0 % 1.38 [ 0.28, 6.71 ]
Total (95% CI) 33 33 100.0 % 1.38 [ 0.28, 6.71 ]
Total events: 4 (500 ug hCG), 3 (250 ug hCG)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours 500 ug hCG Favours 250 ug hCG
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A P P E N D I C E S
Appendix 1. MDSG search strategy
KeywordsCONTAINS “artificial insemination” or “IUI” or “IUI timing” or “Intrauterine Insemination” orTitleCONTAINS “artificial
insemination” or “IUI” or “IUI timing” or “Intrauterine Insemination”
AND
Keywords CONTAINS “human chorionic gonadotrophin” or “human chorionic gonadotropin” or “human menopausal go-
nadotrophin” or “HCG” or “chorionic gonadotrophins” or “GnRH agonist” or “GnRH agonists” or “GnRH analog” or “GnRH
analogue” or “GnRH analogues” or “GnRHa” or “GnRHa-gonadotropin” or “Luteinising hormone releasing hormone” or “luteinizing
hormone” or “Lutenising hormone releasing hormone” or “luteinizing hormone supplementation” or “lh” or “basal body temp” or
“hMG” or “Profasi” or “BBT” or “ultrasonography” or “ultrasound” or “timing LH surge” or “timing of insemination” or “timing
ovulation” or “timing of administration” or “timed intercourse” or “time of insemination”
Appendix 2. CENTRAL search strategy
Central Register of Controlled Trials <1st Quarter 2009>
1 human chorionic gonadotropin.tw. (311)
2 hCG.tw. (829)
3 choriogon$.tw. (5)
4 (pregnyl or chorulon or gonabion).tw. (2)
5 (Luteinizing Hormone or interstitial cell stimulating hormone or lutropin or luteoz?man).ti,ab,sh. (1775)
6 (LH or ICSH).tw. (1829)
7 exp Chorionic Gonadotropin/ (524)
8 body temperature$.tw. (1125)
9 GnRH agonist.tw. (503)
10 GnRH analogue.tw. (110)
11 gonadotropin releasing hormone agonist.tw. (245)
12 GnRHa.tw. (169)
13 HMG.tw. (1026)
14 human menopausal gonadotropin.tw. (169)
15 (profasi or ovitrelle).tw. (9)







23 Artificial Insemination.tw. (51)
24 intrauter$ inseminat$.tw. (329)
25 (intra-uter$ adj2 inseminat$).tw. (25)
26 iui.tw. (227)
27 AIH.tw. (23)
28 exp artificial insemination/ or exp ovulation induction/ (858)
29 or/23-28 (1085)
30 22 and 29 (711)
31 (ivf or icsi).tw. (1833)
32 (in vitro fertilization or intracytoplasmic sperm injection).tw. (1271)
33 or/31-32 (2318)
34 30 not 33 (392)
35 from 34 keep 1-392 (392)
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Cochrane Central Register of Controlled Trials <April 2012>
1 human chorionic gonadotropin.tw. (371)
2 hCG.tw. (981)
3 choriogon$.tw. (5)
4 (pregnyl or chorulon or gonabion).tw. (2)
5 (Luteinizing Hormone or interstitial cell stimulating hormone or lutropin or luteoz?man).ti,ab,sh. (1964)
6 (LH or ICSH).tw. (2030)
7 exp Chorionic Gonadotropin/ (587)
8 body temperature$.tw. (1279)
9 GnRH agonist.tw. (579)
10 GnRH analogue.tw. (123)
11 gonadotropin releasing hormone agonist.tw. (270)
12 GnRHa.tw. (190)
13 HMG.tw. (1112)
14 human menopausal gonadotropin.tw. (182)
15 (profasi or ovitrelle).tw. (10)







23 exp Insemination, Artificial/ (269)
24 Artificial Insemination.tw. (53)
25 intrauter$ inseminat$.tw. (386)




30 22 and 29 (264)
31 limit 30 to yr=“2009 -Current” (38)
Central register of controlled trials < dec 2012>
1 human chorionic gonadotropin.tw. (374)
2 hCG.tw. (995)
3 choriogon$.tw. (5)
4 (pregnyl or chorulon or gonabion).tw. (2)
5 (Luteinizing Hormone or interstitial cell stimulating hormone or lutropin or luteoz?man).ti,ab,sh. (1965)
6 (LH or ICSH).tw. (2040)
7 exp Chorionic Gonadotropin/ (588)
8 body temperature$.tw. (1285)
9 GnRH agonist.tw. (589)
10 GnRH analogue.tw. (124)
11 gonadotropin releasing hormone agonist.tw. (271)
12 GnRHa.tw. (190)
13 HMG.tw. (1116)
14 human menopausal gonadotropin.tw. (182)
15 (profasi or ovitrelle).tw. (10)
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21 timing.tw. (2855)
22 or/1-21 (133854)
23 exp Insemination, Artificial/ (270)
24 Artificial Insemination.tw. (54)
25 intrauter$ inseminat$.tw. (399)




30 22 and 29 (269)
31 limit 30 to yr=“2012 -Current” (3)
Appendix 3. MEDLINE search strategy
MEDLINE ( 1966 to March 2009)
1 human chorionic gonadotropin.tw. (9408)
2 hCG.tw. (17711)
3 choriogon$.tw. (806)
4 (pregnyl or chorulon or gonabion).tw. (49)
5 (Luteinizing Hormone or interstitial cell stimulating hormone or lutropin or luteoz?man).ti,ab,sh. (48292)
6 (LH or ICSH).tw. (39220)
7 exp Chorionic Gonadotropin/ (26357)
8 body temperature$.tw. (17493)
9 GnRH agonist.tw. (2074)
10 GnRH analogue.tw. (610)
11 gonadotropin releasing hormone agonist.tw. (1062)
12 GnRHa.tw. (819)
13 HMG.tw. (10035)
14 human menopausal gonadotropin.tw. (1057)
15 (profasi or ovitrelle).tw. (27)







23 exp Insemination, Artificial/ (8561)
24 Artificial Insemination.tw. (3649)
25 intrauter$ inseminat$.tw. (1295)




30 22 and 29 (2844)
31 randomised controlled trial.pt. (266031)
32 controlled clinical trial.pt. (78661)
33 (randomised or randomised).ab. (210367)
34 placebo.ab. (110319)
35 drug therapy.fs. (1291549)
36 randomly.ab. (128228)
37 trial.ab. (183721)
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38 groups.ab. (888340)
39 or/31-38 (2358832)
40 (animals not (humans and animals)).sh. (3251132)
41 39 not 40 (1999305)
42 30 and 41 (469)
43 (ivf or icsi or intracytoplasmic sperm injection$).tw. (13661)
44 42 not 43 (394)
45 from 44 keep 1-394 (394)
MEDLINE (January 2009 to 07 May 2012)
1 human chorionic gonadotropin.tw. (10613)
2 hCG.tw. (19802)
3 choriogon$.tw. (862)
4 (pregnyl or chorulon or gonabion).tw. (65)
5 (Luteinizing Hormone or interstitial cell stimulating hormone or lutropin or luteoz?man).ti,ab,sh. (51259)
6 (LH or ICSH).tw. (43606)
7 exp Chorionic Gonadotropin/ (28013)
8 body temperature$.tw. (20554)
9 GnRH agonist.tw. (2496)
10 GnRH analogue.tw. (726)
11 gonadotropin releasing hormone agonist.tw. (1204)
12 GnRHa.tw. (984)
13 HMG.tw. (11574)
14 human menopausal gonadotropin.tw. (1093)
15 (profasi or ovitrelle).tw. (30)







23 exp Insemination, Artificial/ (9448)
24 Artificial Insemination.tw. (4477)
25 intrauter$ inseminat$.tw. (1616)




30 22 and 29 (3554)
31 randomized controlled trial.pt. (327017)
32 controlled clinical trial.pt. (84075)
33 randomized.ab. (242418)
34 placebo.tw. (139743)
35 clinical trials as topic.sh. (159870)
36 randomly.ab. (178062)
37 trial.ti. (104315)
38 (crossover or cross-over or cross over).tw. (53309)
39 or/31-38 (801493)
40 exp animals/ not humans.sh. (3712811)
41 39 not 40 (739736)
42 30 and 41 (294)
43 (2009$ or 2010$ or 2011$ or 2012$).ed. (3080766)
44 42 and 43 (56
85Synchronised approach for intrauterine insemination in subfertile couples (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
MEDLINE (May 2012 to 04 Feb 2013)
1 human chorionic gonadotropin.tw. (10853)
2 hCG.tw. (20241)
3 choriogon$.tw. (869)
4 (pregnyl or chorulon or gonabion).tw. (71)
5 (Luteinizing Hormone or interstitial cell stimulating hormone or lutropin or luteoz?man).ti,ab,sh. (51761)
6 (LH or ICSH).tw. (44399)
7 exp Chorionic Gonadotropin/ (28368)
8 body temperature$.tw. (21082)
9 GnRH agonist.tw. (2630)
10 GnRH analogue.tw. (754)
11 gonadotropin releasing hormone agonist.tw. (1260)
12 GnRHa.tw. (1028)
13 HMG.tw. (11735)
14 human menopausal gonadotropin.tw. (1131)
15 (profasi or ovitrelle).tw. (31)







23 exp Insemination, Artificial/ (9640)
24 Artificial Insemination.tw. (4650)
25 intrauter$ inseminat$.tw. (1692)




30 22 and 29 (3735)
31 randomized controlled trial.pt. (339054)
32 controlled clinical trial.pt. (85098)
33 randomized.ab. (256457)
34 placebo.tw. (144132)
35 clinical trials as topic.sh. (162088)
36 randomly.ab. (187749)
37 trial.ti. (109412)
38 (crossover or cross-over or cross over).tw. (55285)
39 or/31-38 (833381)
40 exp animals/ not humans.sh. (3754079)
41 39 not 40 (768269)
42 30 and 41 (306)
43 (2012$ or 2013$).ed. (1118579)
44 42 and 43 (17)
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Appendix 4. EMBASE search strategy
EMBASE (1974 to March 2009)
1 human chorionic gonadotropin.tw. (7671)
2 hCG.tw. (14541)
3 choriogon$.tw. (657)
4 (pregnyl or chorulon or gonabion).tw. (1250)
5 (Luteinizing Hormone or interstitial cell stimulating hormone or lutropin or luteoz?man).ti,ab,sh. (35470)
6 (LH or ICSH).tw. (30151)
7 exp Chorionic Gonadotropin/ (21583)
8 body temperature$.tw. (13145)
9 GnRH agonist.tw. (2019)
10 GnRH analogue.tw. (547)
11 gonadotropin releasing hormone agonist.tw. (1044)
12 GnRHa.tw. (810)
13 HMG.tw. (9668)
14 human menopausal gonadotropin.tw. (970)
15 (profasi or ovitrelle).tw. (1323)







23 Artificial Insemination.tw. (1376)
24 intrauter$ inseminat$.tw. (1274)
25 (intra-uter$ adj2 inseminat$).tw. (144)
26 iui.tw. (845)
27 AIH.tw. (970)
28 exp artificial insemination/ or exp ovulation induction/ (10395)
29 or/23-28 (12514)
30 22 and 29 (6018)
31 Clinical Trial/ (534452)
32 Randomized Controlled Trial/ (166828)
33 exp randomisation/ (26635)
34 Single Blind Procedure/ (8034)
35 Double Blind Procedure/ (71767)
36 Crossover Procedure/ (21100)
37 Placebo/ (124638)
38 Randomi?ed controlled trial$.tw. (32668)
39 Rct.tw. (2683)
40 random allocation.tw. (637)
41 randomly allocated.tw. (10170)
42 allocated randomly.tw. (1350)
43 (allocated adj2 random).tw. (560)
44 Single blind$.tw. (7444)
45 Double blind$.tw. (84622)
46 ((treble or triple) adj blind$).tw. (140)
47 placebo$.tw. (109819)
48 prospective study/ (80677)
49 or/31-48 (702424)
50 case study/ (5962)
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51 case report.tw. (118966)
52 abstract report/ or letter/ (493672)
53 or/50-52 (616305)
54 49 not 53 (677956)
55 30 and 54 (1225)
56 limit 55 to yr=“2008 - 2009” (88)
57 from 56 keep 1-88 (88)
Ovid EMBASE (January 2010 to 07 May 2012)
EMBASE is only searched two years back as the UKCC has hand searched EMBASE to this point and these trials are already in
CENTRAL.
1 human chorionic gonadotropin.tw. (10712)
2 hCG.tw. (22067)
3 choriogon$.tw. (881)
4 (pregnyl or chorulon or gonabion).tw. (1485)
5 (Luteinizing Hormone or interstitial cell stimulating hormone or lutropin or luteoz?man).ti,ab,sh. (54337)
6 (LH or ICSH).tw. (45662)
7 exp Chorionic Gonadotropin/ (34988)
8 body temperature$.tw. (22592)
9 GnRH agonist.tw. (3159)
10 GnRH analogue.tw. (881)
11 gonadotropin releasing hormone agonist.tw. (1335)
12 GnRHa.tw. (1226)
13 HMG.tw. (13943)
14 human menopausal gonadotropin.tw. (1157)
15 (profasi or ovitrelle).tw. (1503)







23 Artificial Insemination.tw. (4325)
24 intrauter$ inseminat$.tw. (2100)
25 (intra-uter$ adj2 inseminat$).tw. (267)
26 iui.tw. (1532)
27 AIH.tw. (1935)
28 exp artificial insemination/ or exp ovulation induction/ (20846)
29 or/23-28 (25228)
30 22 and 29 (10464)
31 Clinical Trial/ (864714)
32 Randomized Controlled Trial/ (320860)
33 exp randomization/ (57970)
34 Single Blind Procedure/ (15808)
35 Double Blind Procedure/ (108521)
36 Crossover Procedure/ (33692)
37 Placebo/ (197302)
38 Randomi?ed controlled trial$.tw. (73975)
39 Rct.tw. (9062)
40 random allocation.tw. (1134)
41 randomly allocated.tw. (16989)
42 allocated randomly.tw. (1796)
43 (allocated adj2 random).tw. (705)
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44 Single blind$.tw. (12061)
45 Double blind$.tw. (126812)
46 ((treble or triple) adj blind$).tw. (265)
47 placebo$.tw. (173231)
48 prospective study/ (202252)
49 or/31-48 (1240932)
50 case study/ (15388)
51 case report.tw. (223558)
52 abstract report/ or letter/ (829909)
53 or/50-52 (1064356)
54 49 not 53 (1206183)
55 30 and 54 (2195)
56 (2010$ or 2011$ or 2012$).em. (2405704)
57 55 and 56 (386)
Ovid Embase (May 2012 to 04 Feb 2013)
1 human chorionic gonadotropin.tw. (11139)
2 hCG.tw. (23106)
3 choriogon$.tw. (896)
4 (pregnyl or chorulon or gonabion).tw. (1535)
5 (Luteinizing Hormone or interstitial cell stimulating hormone or lutropin or luteoz?man).ti,ab,sh. (55784)
6 (LH or ICSH).tw. (47444)
7 exp Chorionic Gonadotropin/ (36305)
8 body temperature$.tw. (23776)
9 GnRH agonist.tw. (3359)
10 GnRH analogue.tw. (934)
11 gonadotropin releasing hormone agonist.tw. (1394)
12 GnRHa.tw. (1315)
13 HMG.tw. (14461)
14 human menopausal gonadotropin.tw. (1174)
15 (profasi or ovitrelle).tw. (1555)







23 Artificial Insemination.tw. (4492)
24 intrauter$ inseminat$.tw. (2229)
25 (intra-uter$ adj2 inseminat$).tw. (277)
26 iui.tw. (1647)
27 AIH.tw. (2159)
28 exp artificial insemination/ or exp ovulation induction/ (21522)
29 or/23-28 (26288)
30 22 and 29 (10961)
31 Clinical Trial/ (876466)
32 Randomized Controlled Trial/ (336673)
33 exp randomization/ (60661)
34 Single Blind Procedure/ (16967)
35 Double Blind Procedure/ (112989)
36 Crossover Procedure/ (36118)
37 Placebo/ (212667)
38 Randomi?ed controlled trial$.tw. (83349)
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39 Rct.tw. (10867)
40 random allocation.tw. (1206)
41 randomly allocated.tw. (18256)
42 allocated randomly.tw. (1863)
43 (allocated adj2 random).tw. (716)
44 Single blind$.tw. (13000)
45 Double blind$.tw. (133772)
46 ((treble or triple) adj blind$).tw. (300)
47 placebo$.tw. (184418)
48 prospective study/ (224710)
49 or/31-48 (1305860)
50 case study/ (18516)
51 case report.tw. (238003)
52 abstract report/ or letter/ (857366)
53 or/50-52 (1108963)
54 49 not 53 (1269963)
55 30 and 54 (2283)
56 (2012$ or 2013$).em. (1409980)
57 55 and 56 (146)
Appendix 5. PsycINFO search strategy
PsycINFO <1806 to March Week 3 2009>
1 human chorionic gonadotropin.tw. (44)
2 hCG.tw. (42)
3 choriogon$.tw. (0)
4 (pregnyl or chorulon or gonabion).tw. (0)
5 (Luteinizing Hormone or interstitial cell stimulating hormone or lutropin or luteoz?man).ti,ab,sh. (968)
6 (LH or ICSH).tw. (1789)
7 exp Chorionic Gonadotropin/ (0)
8 body temperature$.tw. (2652)
9 GnRH agonist.tw. (22)
10 GnRH analogue.tw. (3)
11 gonadotropin releasing hormone agonist.tw. (25)
12 GnRHa.tw. (9)
13 HMG.tw. (70)
14 human menopausal gonadotropin.tw. (3)
15 (profasi or ovitrelle).tw. (0)







23 Artificial Insemination.tw. (198)
24 intrauter$ inseminat$.tw. (4)
25 (intra-uter$ adj2 inseminat$).tw. (0)
26 iui.tw. (10)
27 AIH.tw. (8)
28 exp artificial insemination/ or exp ovulation induction/ (861)
29 or/23-28 (970)
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30 22 and 29 (121)
31 from 30 keep 1-121 (121)
Database: PsycINFO <1806 to May Week 1 2012>
1 human chorionic gonadotropin.tw. (65)
2 hCG.tw. (64)
3 (pregnyl or chorulon or gonabion).tw. (1)
4 (Luteinizing Hormone or interstitial cell stimulating hormone or lutropin or luteoz?man).ti,ab,sh. (1161)
5 (LH or ICSH).tw. (2202)
6 body temperature$.tw. (3106)
7 GnRH agonist.tw. (33)
8 GnRH analogue.tw. (7)
9 gonadotropin releasing hormone agonist.tw. (28)
10 GnRHa.tw. (19)
11 HMG.tw. (126)
12 human menopausal gonadotropin.tw. (3)
13 (profasi or ovitrelle).tw. (0)







21 Artificial Insemination.tw. (211)








30 clinical trials/ (6006)
31 placebo/ (3203)
32 exp Treatment/ (514585)
33 or/27-32 (779748)
34 26 and 33 (10)
35 limit 34 to yr=“2009 -Current” (4)
PsycINFO <1806 to January Week 5 2013>
1 human chorionic gonadotropin.tw. (66)
2 hCG.tw. (65)
3 (pregnyl or chorulon or gonabion).tw. (1)
4 (Luteinizing Hormone or interstitial cell stimulating hormone or lutropin or luteoz?man).ti,ab,sh. (1200)
5 (LH or ICSH).tw. (2299)
6 body temperature$.tw. (3205)
7 GnRH agonist.tw. (37)
8 GnRH analogue.tw. (7)
9 gonadotropin releasing hormone agonist.tw. (30)
10 GnRHa.tw. (19)
11 HMG.tw. (143)
12 human menopausal gonadotropin.tw. (3)
13 (profasi or ovitrelle).tw. (0)
14 gonadotrophin releasing hormone agonist.tw. (2)
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21 Artificial Insemination.tw. (215)








30 clinical trials/ (6539)
31 placebo/ (3372)
32 exp Treatment/ (536873)
33 or/27-32 (816147)
34 26 and 33 (11)
35 limit 34 to yr=“2012 - 2013” (1)
Appendix 6. Other electronic sources search strategy (PubMed)
intrauterine; intra uterine; intra-uterine; insemination; inseminate; IUI; artificial insemination; AI; Artificial insemination husband;
AIH; timing; hCG; human chorionic gonadotropin; human chorionic gonadotrophin; gonadotrophins; Pregnyl; Ovitrelle; Profasi;
GnRH agonist; GnRH agonists; GnRH analogue; GnRH analogue; GnRH analogues; GnRHa; GnRHa-gonadotropin; Luteinising
hormone; Luteinising hormone releasing hormone; LH; LH surge; LH determination; LH rise; LH detection kit; urinary LH; basal
body temp; BBT; hMG; ultrasonography; ultrasound; timing of insemination; timing ovulation; timing of administration; subfertile;
subfertility; infertility; (randomised controlled trial [Publication Type], controlled clinical trial [Publication Type], randomised con-
trolled trials, random allocation, double-blind method, single-blind method, clinical trial [Publication Type], clinical trials, (clinical
AND trial*)).
Appendix 7. Search string
MEDLINE (1966 to March 2009)
1 human chorionic gonadotropin.tw. (9408)
2 hCG.tw. (17711)
3 choriogon$.tw. (806)
4 (pregnyl or chorulon or gonabion).tw. (49)
5 (Luteinizing Hormone or interstitial cell stimulating hormone or lutropin or luteoz?man).ti,ab,sh. (48292)
6 (LH or ICSH).tw. (39220)
7 exp Chorionic Gonadotropin/ (26357)
8 body temperature$.tw. (17493)
9 GnRH agonist.tw. (2074)
10 GnRH analogue.tw. (610)
11 gonadotropin releasing hormone agonist.tw. (1062)
12 GnRHa.tw. (819)
13 HMG.tw. (10035)
14 human menopausal gonadotropin.tw. (1057)
15 (profasi or ovitrelle).tw. (27)
16 gonadotrophin releasing hormone agonist.tw. (302)
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23 exp Insemination, Artificial/ (8561)
24 Artificial Insemination.tw. (3649)
25 intrauter$ inseminat$.tw. (1295)




30 22 and 29 (2844)
31 randomised controlled trial.pt. (266031)
32 controlled clinical trial.pt. (78661)
33 (randomised or randomised).ab. (210367)
34 placebo.ab. (110319)





40 (animals not (humans and animals)).sh. (3251132)
41 39 not 40 (1999305)
42 30 and 41 (469)
43 (ivf or icsi or intracytoplasmic sperm injection$).tw. (13661)
44 42 not 43 (394)
45 from 44 keep 1-394 (394)
MEDLINE (January 2009 to 07 May 2012)
1 human chorionic gonadotropin.tw. (10613)
2 hCG.tw. (19802)
3 choriogon$.tw. (862)
4 (pregnyl or chorulon or gonabion).tw. (65)
5 (Luteinizing Hormone or interstitial cell stimulating hormone or lutropin or luteoz?man).ti,ab,sh. (51259)
6 (LH or ICSH).tw. (43606)
7 exp Chorionic Gonadotropin/ (28013)
8 body temperature$.tw. (20554)
9 GnRH agonist.tw. (2496)
10 GnRH analogue.tw. (726)
11 gonadotropin releasing hormone agonist.tw. (1204)
12 GnRHa.tw. (984)
13 HMG.tw. (11574)
14 human menopausal gonadotropin.tw. (1093)
15 (profasi or ovitrelle).tw. (30)







23 exp Insemination, Artificial/ (9448)
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24 Artificial Insemination.tw. (4477)
25 intrauter$ inseminat$.tw. (1616)




30 22 and 29 (3554)
31 randomized controlled trial.pt. (327017)
32 controlled clinical trial.pt. (84075)
33 randomized.ab. (242418)
34 placebo.tw. (139743)
35 clinical trials as topic.sh. (159870)
36 randomly.ab. (178062)
37 trial.ti. (104315)
38 (crossover or cross-over or cross over).tw. (53309)
39 or/31-38 (801493)
40 exp animals/ not humans.sh. (3712811)
41 39 not 40 (739736)
42 30 and 41 (294)
43 (2009$ or 2010$ or 2011$ or 2012$).ed. (3080766)
44 42 and 43 (56
MEDLINE (May 2012 to 04 Feb 2013)
1 human chorionic gonadotropin.tw. (10853)
2 hCG.tw. (20241)
3 choriogon$.tw. (869)
4 (pregnyl or chorulon or gonabion).tw. (71)
5 (Luteinizing Hormone or interstitial cell stimulating hormone or lutropin or luteoz?man).ti,ab,sh. (51761)
6 (LH or ICSH).tw. (44399)
7 exp Chorionic Gonadotropin/ (28368)
8 body temperature$.tw. (21082)
9 GnRH agonist.tw. (2630)
10 GnRH analogue.tw. (754)
11 gonadotropin releasing hormone agonist.tw. (1260)
12 GnRHa.tw. (1028)
13 HMG.tw. (11735)
14 human menopausal gonadotropin.tw. (1131)
15 (profasi or ovitrelle).tw. (31)







23 exp Insemination, Artificial/ (9640)
24 Artificial Insemination.tw. (4650)
25 intrauter$ inseminat$.tw. (1692)




30 22 and 29 (3735)
31 randomized controlled trial.pt. (339054)
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32 controlled clinical trial.pt. (85098)
33 randomized.ab. (256457)
34 placebo.tw. (144132)
35 clinical trials as topic.sh. (162088)
36 randomly.ab. (187749)
37 trial.ti. (109412)
38 (crossover or cross-over or cross over).tw. (55285)
39 or/31-38 (833381)
40 exp animals/ not humans.sh. (3754079)
41 39 not 40 (768269)
42 30 and 41 (306)
43 (2012$ or 2013$).ed. (1118579)
44 42 and 43 (17)
EMBASE (1974 to March 2009)
1 human chorionic gonadotropin.tw. (7671)
2 hCG.tw. (14541)
3 choriogon$.tw. (657)
4 (pregnyl or chorulon or gonabion).tw. (1250)
5 (Luteinizing Hormone or interstitial cell stimulating hormone or lutropin or luteoz?man).ti,ab,sh. (35470)
6 (LH or ICSH).tw. (30151)
7 exp Chorionic Gonadotropin/ (21583)
8 body temperature$.tw. (13145)
9 GnRH agonist.tw. (2019)
10 GnRH analogue.tw. (547)
11 gonadotropin releasing hormone agonist.tw. (1044)
12 GnRHa.tw. (810)
13 HMG.tw. (9668)
14 human menopausal gonadotropin.tw. (970)
15 (profasi or ovitrelle).tw. (1323)







23 Artificial Insemination.tw. (1376)
24 intrauter$ inseminat$.tw. (1274)
25 (intra-uter$ adj2 inseminat$).tw. (144)
26 iui.tw. (845)
27 AIH.tw. (970)
28 exp artificial insemination/ or exp ovulation induction/ (10395)
29 or/23-28 (12514)
30 22 and 29 (6018)
31 Clinical Trial/ (534452)
32 Randomized Controlled Trial/ (166828)
33 exp randomisation/ (26635)
34 Single Blind Procedure/ (8034)
35 Double Blind Procedure/ (71767)
36 Crossover Procedure/ (21100)
37 Placebo/ (124638)
38 Randomi?ed controlled trial$.tw. (32668)
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39 Rct.tw. (2683)
40 random allocation.tw. (637)
41 randomly allocated.tw. (10170)
42 allocated randomly.tw. (1350)
43 (allocated adj2 random).tw. (560)
44 Single blind$.tw. (7444)
45 Double blind$.tw. (84622)
46 ((treble or triple) adj blind$).tw. (140)
47 placebo$.tw. (109819)
48 prospective study/ (80677)
49 or/31-48 (702424)
50 case study/ (5962)
51 case report.tw. (118966)
52 abstract report/ or letter/ (493672)
53 or/50-52 (616305)
54 49 not 53 (677956)
55 30 and 54 (1225)
56 limit 55 to yr=“2008 - 2009” (88)
57 from 56 keep 1-88 (88)
Ovid EMBASE (January 2010 to 07 May 2012)
EMBASE is only searched two years back as the UKCC has hand searched EMBASE to this point and these trials are already in
CENTRAL.
1 human chorionic gonadotropin.tw. (10712)
2 hCG.tw. (22067)
3 choriogon$.tw. (881)
4 (pregnyl or chorulon or gonabion).tw. (1485)
5 (Luteinizing Hormone or interstitial cell stimulating hormone or lutropin or luteoz?man).ti,ab,sh. (54337)
6 (LH or ICSH).tw. (45662)
7 exp Chorionic Gonadotropin/ (34988)
8 body temperature$.tw. (22592)
9 GnRH agonist.tw. (3159)
10 GnRH analogue.tw. (881)
11 gonadotropin releasing hormone agonist.tw. (1335)
12 GnRHa.tw. (1226)
13 HMG.tw. (13943)
14 human menopausal gonadotropin.tw. (1157)
15 (profasi or ovitrelle).tw. (1503)







23 Artificial Insemination.tw. (4325)
24 intrauter$ inseminat$.tw. (2100)
25 (intra-uter$ adj2 inseminat$).tw. (267)
26 iui.tw. (1532)
27 AIH.tw. (1935)
28 exp artificial insemination/ or exp ovulation induction/ (20846)
29 or/23-28 (25228)
30 22 and 29 (10464)
31 Clinical Trial/ (864714)
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32 Randomized Controlled Trial/ (320860)
33 exp randomization/ (57970)
34 Single Blind Procedure/ (15808)
35 Double Blind Procedure/ (108521)
36 Crossover Procedure/ (33692)
37 Placebo/ (197302)
38 Randomi?ed controlled trial$.tw. (73975)
39 Rct.tw. (9062)
40 random allocation.tw. (1134)
41 randomly allocated.tw. (16989)
42 allocated randomly.tw. (1796)
43 (allocated adj2 random).tw. (705)
44 Single blind$.tw. (12061)
45 Double blind$.tw. (126812)
46 ((treble or triple) adj blind$).tw. (265)
47 placebo$.tw. (173231)
48 prospective study/ (202252)
49 or/31-48 (1240932)
50 case study/ (15388)
51 case report.tw. (223558)
52 abstract report/ or letter/ (829909)
53 or/50-52 (1064356)
54 49 not 53 (1206183)
55 30 and 54 (2195)
56 (2010$ or 2011$ or 2012$).em. (2405704)
57 55 and 56 (386)
Ovid EMBASE (May 2012 to 04 Feb 2013)
1 human chorionic gonadotropin.tw. (11139)
2 hCG.tw. (23106)
3 choriogon$.tw. (896)
4 (pregnyl or chorulon or gonabion).tw. (1535)
5 (Luteinizing Hormone or interstitial cell stimulating hormone or lutropin or luteoz?man).ti,ab,sh. (55784)
6 (LH or ICSH).tw. (47444)
7 exp Chorionic Gonadotropin/ (36305)
8 body temperature$.tw. (23776)
9 GnRH agonist.tw. (3359)
10 GnRH analogue.tw. (934)
11 gonadotropin releasing hormone agonist.tw. (1394)
12 GnRHa.tw. (1315)
13 HMG.tw. (14461)
14 human menopausal gonadotropin.tw. (1174)
15 (profasi or ovitrelle).tw. (1555)







23 Artificial Insemination.tw. (4492)
24 intrauter$ inseminat$.tw. (2229)
25 (intra-uter$ adj2 inseminat$).tw. (277)
26 iui.tw. (1647)
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27 AIH.tw. (2159)
28 exp artificial insemination/ or exp ovulation induction/ (21522)
29 or/23-28 (26288)
30 22 and 29 (10961)
31 Clinical Trial/ (876466)
32 Randomized Controlled Trial/ (336673)
33 exp randomization/ (60661)
34 Single Blind Procedure/ (16967)
35 Double Blind Procedure/ (112989)
36 Crossover Procedure/ (36118)
37 Placebo/ (212667)
38 Randomi?ed controlled trial$.tw. (83349)
39 Rct.tw. (10867)
40 random allocation.tw. (1206)
41 randomly allocated.tw. (18256)
42 allocated randomly.tw. (1863)
43 (allocated adj2 random).tw. (716)
44 Single blind$.tw. (13000)
45 Double blind$.tw. (133772)
46 ((treble or triple) adj blind$).tw. (300)
47 placebo$.tw. (184418)
48 prospective study/ (224710)
49 or/31-48 (1305860)
50 case study/ (18516)
51 case report.tw. (238003)
52 abstract report/ or letter/ (857366)
53 or/50-52 (1108963)
54 49 not 53 (1269963)
55 30 and 54 (2283)
56 (2012$ or 2013$).em. (1409980)
57 55 and 56 (146)
Central Register of Controlled Trials <1st Quarter 2009>
1 human chorionic gonadotropin.tw. (311)
2 hCG.tw. (829)
3 choriogon$.tw. (5)
4 (pregnyl or chorulon or gonabion).tw. (2)
5 (Luteinizing Hormone or interstitial cell stimulating hormone or lutropin or luteoz?man).ti,ab,sh. (1775)
6 (LH or ICSH).tw. (1829)
7 exp Chorionic Gonadotropin/ (524)
8 body temperature$.tw. (1125)
9 GnRH agonist.tw. (503)
10 GnRH analogue.tw. (110)
11 gonadotropin releasing hormone agonist.tw. (245)
12 GnRHa.tw. (169)
13 HMG.tw. (1026)
14 human menopausal gonadotropin.tw. (169)
15 (profasi or ovitrelle).tw. (9)
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21 timing.tw. (2259)
22 or/1-21 (110066)
23 Artificial Insemination.tw. (51)
24 intrauter$ inseminat$.tw. (329)
25 (intra-uter$ adj2 inseminat$).tw. (25)
26 iui.tw. (227)
27 AIH.tw. (23)
28 exp artificial insemination/ or exp ovulation induction/ (858)
29 or/23-28 (1085)
30 22 and 29 (711)
31 (ivf or icsi).tw. (1833)
32 (in vitro fertilization or intracytoplasmic sperm injection).tw. (1271)
33 or/31-32 (2318)
34 30 not 33 (392)
35 from 34 keep 1-392 (392)
Cochrane Central Register of Controlled Trials <April 2012>
1 human chorionic gonadotropin.tw. (371)
2 hCG.tw. (981)
3 choriogon$.tw. (5)
4 (pregnyl or chorulon or gonabion).tw. (2)
5 (Luteinizing Hormone or interstitial cell stimulating hormone or lutropin or luteoz?man).ti,ab,sh. (1964)
6 (LH or ICSH).tw. (2030)
7 exp Chorionic Gonadotropin/ (587)
8 body temperature$.tw. (1279)
9 GnRH agonist.tw. (579)
10 GnRH analogue.tw. (123)
11 gonadotropin releasing hormone agonist.tw. (270)
12 GnRHa.tw. (190)
13 HMG.tw. (1112)
14 human menopausal gonadotropin.tw. (182)
15 (profasi or ovitrelle).tw. (10)







23 exp Insemination, Artificial/ (269)
24 Artificial Insemination.tw. (53)
25 intrauter$ inseminat$.tw. (386)




30 22 and 29 (264)
31 limit 30 to yr=“2009 -Current” (38)
Central register of controlled trials < dec 2012>
1 human chorionic gonadotropin.tw. (374)
2 hCG.tw. (995)
3 choriogon$.tw. (5)
4 (pregnyl or chorulon or gonabion).tw. (2)
5 (Luteinizing Hormone or interstitial cell stimulating hormone or lutropin or luteoz?man).ti,ab,sh. (1965)
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6 (LH or ICSH).tw. (2040)
7 exp Chorionic Gonadotropin/ (588)
8 body temperature$.tw. (1285)
9 GnRH agonist.tw. (589)
10 GnRH analogue.tw. (124)
11 gonadotropin releasing hormone agonist.tw. (271)
12 GnRHa.tw. (190)
13 HMG.tw. (1116)
14 human menopausal gonadotropin.tw. (182)
15 (profasi or ovitrelle).tw. (10)







23 exp Insemination, Artificial/ (270)
24 Artificial Insemination.tw. (54)
25 intrauter$ inseminat$.tw. (399)




30 22 and 29 (269)
31 limit 30 to yr=“2012 -Current” (3)
PsycINFO <1806 to March Week 3 2009>
1 human chorionic gonadotropin.tw. (44)
2 hCG.tw. (42)
3 choriogon$.tw. (0)
4 (pregnyl or chorulon or gonabion).tw. (0)
5 (Luteinizing Hormone or interstitial cell stimulating hormone or lutropin or luteoz?man).ti,ab,sh. (968)
6 (LH or ICSH).tw. (1789)
7 exp Chorionic Gonadotropin/ (0)
8 body temperature$.tw. (2652)
9 GnRH agonist.tw. (22)
10 GnRH analogue.tw. (3)
11 gonadotropin releasing hormone agonist.tw. (25)
12 GnRHa.tw. (9)
13 HMG.tw. (70)
14 human menopausal gonadotropin.tw. (3)
15 (profasi or ovitrelle).tw. (0)







23 Artificial Insemination.tw. (198)
24 intrauter$ inseminat$.tw. (4)
25 (intra-uter$ adj2 inseminat$).tw. (0)
26 iui.tw. (10)
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27 AIH.tw. (8)
28 exp artificial insemination/ or exp ovulation induction/ (861)
29 or/23-28 (970)
30 22 and 29 (121)
31 from 30 keep 1-121 (121)
Database: PsycINFO <1806 to May Week 1 2012>
1 human chorionic gonadotropin.tw. (65)
2 hCG.tw. (64)
3 (pregnyl or chorulon or gonabion).tw. (1)
4 (Luteinizing Hormone or interstitial cell stimulating hormone or lutropin or luteoz?man).ti,ab,sh. (1161)
5 (LH or ICSH).tw. (2202)
6 body temperature$.tw. (3106)
7 GnRH agonist.tw. (33)
8 GnRH analogue.tw. (7)
9 gonadotropin releasing hormone agonist.tw. (28)
10 GnRHa.tw. (19)
11 HMG.tw. (126)
12 human menopausal gonadotropin.tw. (3)
13 (profasi or ovitrelle).tw. (0)







21 Artificial Insemination.tw. (211)








30 clinical trials/ (6006)
31 placebo/ (3203)
32 exp Treatment/ (514585)
33 or/27-32 (779748)
34 26 and 33 (10)
35 limit 34 to yr=“2009 -Current” (4)
PsycINFO <1806 to January Week 5 2013>
1 human chorionic gonadotropin.tw. (66)
2 hCG.tw. (65)
3 (pregnyl or chorulon or gonabion).tw. (1)
4 (Luteinizing Hormone or interstitial cell stimulating hormone or lutropin or luteoz?man).ti,ab,sh. (1200)
5 (LH or ICSH).tw. (2299)
6 body temperature$.tw. (3205)
7 GnRH agonist.tw. (37)
8 GnRH analogue.tw. (7)
9 gonadotropin releasing hormone agonist.tw. (30)
10 GnRHa.tw. (19)
11 HMG.tw. (143)
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12 human menopausal gonadotropin.tw. (3)
13 (profasi or ovitrelle).tw. (0)







21 Artificial Insemination.tw. (215)








30 clinical trials/ (6539)
31 placebo/ (3372)
32 exp Treatment/ (536873)
33 or/27-32 (816147)
34 26 and 33 (11)
35 limit 34 to yr=“2012 - 2013” (1)
WH A T ’ S N E W
Last assessed as up-to-date: 15 October 2014.
Date Event Description
15 October 2014 New search has been performed Eight new trials were included in the review (
AboulGheit 2010; da Silva 2012; Kyrou 2012;
Nikbakht 2012; Rahman 2011; Sharma 2011;
Schmidt-Sarosi 1995; Weiss 2010). Four studies were
placed in awaiting classification (Aydin 2013; Blockeel
2014; Dehghani 2014; Mostafa 2014).
15 October 2014 New citation required but conclusions have not
changed
Based on the new meta-analysis the conclusions are not
changed
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H I S T O R Y
Protocol first published: Issue 1, 2008
Review first published: Issue 4, 2010
Date Event Description
6 July 2009 Amended The protocol stated that no couples with cycle disturbances should be included, however almost
all studies, apart from in unexplained subfertility and male subfertility, also included a category
of women with cycle disturbances. We accepted this when only a some of the included couples
belonged to this category
10 November 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
Astrid Cantineau: title registration; substantial contribution to developing protocol; reviewing articles for inclusion in review and
update; substantial contribution writing review.
Mirjam Janssen: writing the protocol; performing search, selection of articles; substantial contribution writing review and update.
Ben Cohlen: formulation of research question; critical view on protocol; arbitration with reviewing the articles; substantial contribution
writing review and update.
Thomas Allersma: reviewing articles for inclusion in updated review; substantial contribution writing update.
D E C L A R A T I O N S O F I N T E R E S T
None known for any of the review authors.





103Synchronised approach for intrauterine insemination in subfertile couples (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The protocol stated that women with ovulatory disturbances should not be included. Since the available evidence was scarce we decided
to include studies where a proportion of the included women suffered from ovulatory disturbances. In the updated version we were
more liberal towards whether a study was truly randomised; when the trial design did not mention the allocation concealment certain
studies were included, identifying it as at high risk on bias in the table of included studies.
The protocol stated that if more than 10% of the cycles were cancelled, these data would not be incorporated in the meta-analysis.
Since only a few studies were available, higher dropout rates and cancelled cycles were accepted in the published version as well as in
the updated version of the review.
The protocol stated that we would report miscarriage and multiple pregnancy results per woman randomised. For the full review and
this update we reported miscarriage and multiple pregnancy results per pregnancy.
2014 update: methods sections updated to current Cochrane recommendations.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Body Temperature; Chorionic Gonadotropin [administration & dosage]; Gonadotropin-Releasing Hormone [agonists]; Infertility
[∗therapy]; Insemination, Artificial [∗methods]; Luteinizing Hormone [blood; urine]; Ovulation Detection [methods]; Randomized
Controlled Trials as Topic; Time Factors
MeSH check words
Adult; Female; Humans; Male; Young Adult
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